Title: LEGISLATIVE BILL 431
Official Title: LEGISLATIVE BILL 431
Number of Sections: 1
Source: versions - Introduced
Media Type: application/pdf
Strikethrough Detection: 46 sections found

================================================================================

Section 1:
LB431 LB431
2025 2025
LEGISLATURE OF NEBRASKA
ONE HUNDRED NINTH LEGISLATURE
FIRST SESSION
Introduced by Lippincott, 34; Murman, 38.
Read first time January 17, 2025
Committee: Judiciary
1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to
2 amend sections 28-401 and 28-405, Revised Statutes Cumulative
3 Supplement, 2024; to prohibit kratom as a controlled substance; to
4 define a term; and to repeal the original sections.
5 Be it enacted by the people of the State of Nebraska,
-1-
LB431 LB431
2025 2025
1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement,
2 2024, is amended to read:
3 28-401 As used in the Uniform Controlled Substances Act, unless the
4 context otherwise requires:
5 (1) Administer means to directly apply a controlled substance by
6 injection, inhalation, ingestion, or any other means to the body of a
7 patient or research subject;
8 (2) Agent means an authorized person who acts on behalf of or at the
9 direction of another person but does not include a common or contract
10 carrier, public warehouse keeper, or employee of a carrier or warehouse
11 keeper;
12 (3) Administration means the Drug Enforcement Administration of the
13 United States Department of Justice;
14 (4) Controlled substance means a drug, biological, substance, or
15 immediate precursor in Schedules I through V of section 28-405.
16 Controlled substance does not include distilled spirits, wine, malt
17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance
18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et
19 seq., as such act existed on January 1, 2014, and the law of this state,
20 be lawfully sold over the counter without a prescription;
21 (5) Counterfeit substance means a controlled substance which, or the
22 container or labeling of which, without authorization, bears the
23 trademark, trade name, or other identifying mark, imprint, number, or
24 device, or any likeness thereof, of a manufacturer, distributor, or
25 dispenser other than the person or persons who in fact manufactured,
26 distributed, or dispensed such substance and which thereby falsely
27 purports or is represented to be the product of, or to have been
28 distributed by, such other manufacturer, distributor, or dispenser;
29 (6) Department means the Department of Health and Human Services;
30 (7) Division of Drug Control means the personnel of the Nebraska
31 State Patrol who are assigned to enforce the Uniform Controlled
-2-
LB431 LB431
2025 2025
1 Substances Act;
2 (8) Dispense means to deliver a controlled substance to an ultimate
3 user or a research subject pursuant to a medical order issued by a
4 practitioner authorized to prescribe, including the packaging, labeling,
5 or compounding necessary to prepare the controlled substance for such
6 delivery;
7 (9) Distribute means to deliver other than by administering or
8 dispensing a controlled substance;
9 (10) Prescribe means to issue a medical order;
10 (11) Drug means (a) articles recognized in the official United
11 States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United
12 States, official National Formulary, or any supplement to any of them,
13 (b) substances intended for use in the diagnosis, cure, mitigation,
14 treatment, or prevention of disease in human beings or animals, and (c)
15 substances intended for use as a component of any article specified in
16 subdivision (a) or (b) of this subdivision, but does not include devices
17 or their components, parts, or accessories;
18 (12) Deliver or delivery means the actual, constructive, or
19 attempted transfer from one person to another of a controlled substance,
20 whether or not there is an agency relationship;
21 (13) Hemp has the same meaning as in section 2-503;
22 (14)(a) Marijuana means all parts of the plant of the genus
23 cannabis, whether growing or not, the seeds thereof, and every compound,
24 manufacture, salt, derivative, mixture, or preparation of such plant or
25 its seeds.
26 (b) Marijuana does not include the mature stalks of such plant,
27 hashish, tetrahydrocannabinols extracted or isolated from the plant,
28 fiber produced from such stalks, oil or cake made from the seeds of such
29 plant, any other compound, manufacture, salt, derivative, mixture, or
30 preparation of such mature stalks, the sterilized seed of such plant
31 which is incapable of germination, or cannabidiol contained in a drug
-3-
LB431 LB431
2025 2025
1 product approved by the federal Food and Drug Administration.
2 (c) Marijuana does not include hemp.
3 (d) When the weight of marijuana is referred to in the Uniform
4 Controlled Substances Act, it means its weight at or about the time it is
5 seized or otherwise comes into the possession of law enforcement
6 authorities, whether cured or uncured at that time;
7 (15) Manufacture means the production, preparation, propagation,
8 conversion, or processing of a controlled substance, either directly or
9 indirectly, by extraction from substances of natural origin,
10 independently by means of chemical synthesis, or by a combination of
11 extraction and chemical synthesis, and includes any packaging or
12 repackaging of the substance or labeling or relabeling of its container.
13 Manufacture does not include the preparation or compounding of a
14 controlled substance by an individual for his or her own use, except for
15 the preparation or compounding of components or ingredients used for or
16 intended to be used for the manufacture of methamphetamine, or the
17 preparation, compounding, conversion, packaging, or labeling of a
18 controlled substance: (a) By a practitioner as an incident to his or her
19 prescribing, administering, or dispensing of a controlled substance in
20 the course of his or her professional practice; or (b) by a practitioner,
21 or by his or her authorized agent under his or her supervision, for the
22 purpose of, or as an incident to, research, teaching, or chemical
23 analysis and not for sale;
24 (16) Narcotic drug means any of the following, whether produced
25 directly or indirectly by extraction from substances of vegetable origin,
26 independently by means of chemical synthesis, or by a combination of
27 extraction and chemical synthesis: (a) Opium, opium poppy and poppy
28 straw, coca leaves, and opiates; (b) a compound, manufacture, salt,
29 derivative, or preparation of opium, coca leaves, or opiates; or (c) a
30 substance and any compound, manufacture, salt, derivative, or preparation
31 thereof which is chemically equivalent to or identical with any of the
-4-
LB431 LB431
2025 2025
1 substances referred to in subdivisions (a) and (b) of this subdivision,
2 except that the words narcotic drug as used in the Uniform Controlled
3 Substances Act does not include decocainized coca leaves or extracts of
4 coca leaves, which extracts do not contain cocaine or ecgonine, or
5 isoquinoline alkaloids of opium;
6 (17) Opiate means any substance having an addiction-forming or
7 addiction-sustaining liability similar to morphine or being capable of
8 conversion into a drug having such addiction-forming or addiction-
9 sustaining liability. Opiate does not include the dextrorotatory isomer
10 of 3-methoxy-n methylmorphinan and its salts. Opiate includes its racemic
11 and levorotatory forms;
12 (18) Opium poppy means the plant of the species Papaver somniferum
13 L., except the seeds thereof;
14 (19) Poppy straw means all parts, except the seeds, of the opium
15 poppy after mowing;
16 (20) Person means any corporation, association, partnership, limited
17 liability company, or one or more persons;
18 (21) Practitioner means a physician, a physician assistant, a
19 dentist, a veterinarian, a pharmacist, a podiatrist, an optometrist, a
20 certified nurse midwife, a certified registered nurse anesthetist, a
21 nurse practitioner, a scientific investigator, a pharmacy, a hospital, or
22 any other person licensed, registered, or otherwise permitted to
23 distribute, dispense, prescribe, conduct research with respect to, or
24 administer a controlled substance in the course of practice or research
25 in this state, including an emergency medical service as defined in
26 section 38-1207;
27 (22) Production includes the manufacture, planting, cultivation, or
28 harvesting of a controlled substance;
29 (23) Immediate precursor means a substance which is the principal
30 compound commonly used or produced primarily for use and which is an
31 immediate chemical intermediary used or likely to be used in the
-5-
LB431 LB431
2025 2025
1 manufacture of a controlled substance, the control of which is necessary
2 to prevent, curtail, or limit such manufacture;
3 (24) State means the State of Nebraska;
4 (25) Ultimate user means a person who lawfully possesses a
5 controlled substance for his or her own use, for the use of a member of
6 his or her household, or for administration to an animal owned by him or
7 her or by a member of his or her household;
8 (26) Hospital has the same meaning as in section 71-419;
9 (27) Cooperating individual means any person, other than a
10 commissioned law enforcement officer, who acts on behalf of, at the
11 request of, or as agent for a law enforcement agency for the purpose of
12 gathering or obtaining evidence of offenses punishable under the Uniform
13 Controlled Substances Act;
14 (28)(a) Hashish or concentrated cannabis means (i) the separated
15 resin, whether crude or purified, obtained from a plant of the genus
16 cannabis or (ii) any material, preparation, mixture, compound, or other
17 substance which contains ten percent or more by weight of
18 tetrahydrocannabinols.
19 (b) When resins extracted from hemp as defined in section 2-503 are
20 in the possession of a person as authorized under the Nebraska Hemp
21 Farming Act, they are not considered hashish or concentrated cannabis for
22 purposes of the Uniform Controlled Substances Act.
23 (c) Hashish or concentrated cannabis does not include cannabidiol
24 contained in a drug product approved by the federal Food and Drug
25 Administration;
26 (29) Exceptionally hazardous drug means (a) a narcotic drug, (b)
27 thiophene analog of phencyclidine, (c) phencyclidine, (d) amobarbital,
28 (e) secobarbital, (f) pentobarbital, (g) amphetamine, or (h)
29 methamphetamine;
30 (30) Imitation controlled substance means a substance which is not a
31 controlled substance or controlled substance analogue but which, by way
-6-
LB431 LB431
2025 2025
1 of express or implied representations and consideration of other relevant
2 factors including those specified in section 28-445, would lead a
3 reasonable person to believe the substance is a controlled substance or
4 controlled substance analogue. A placebo or registered investigational
5 drug manufactured, distributed, possessed, or delivered in the ordinary
6 course of practice or research by a health care professional shall not be
7 deemed to be an imitation controlled substance;
8 (31)(a) Controlled substance analogue means a substance (i) the
9 chemical structure of which is substantially similar to the chemical
10 structure of a Schedule I or Schedule II controlled substance as provided
11 in section 28-405 or (ii) which has a stimulant, depressant, analgesic,
12 or hallucinogenic effect on the central nervous system that is
13 substantially similar to or greater than the stimulant, depressant,
14 analgesic, or hallucinogenic effect on the central nervous system of a
15 Schedule I or Schedule II controlled substance as provided in section
16 28-405. A controlled substance analogue shall, to the extent intended for
17 human consumption, be treated as a controlled substance under Schedule I
18 of section 28-405 for purposes of the Uniform Controlled Substances Act;
19 and
20 (b) Controlled substance analogue does not include (i) a controlled
21 substance, (ii) any substance generally recognized as safe and effective
22 within the meaning of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
23 301 et seq., as such act existed on January 1, 2014, (iii) any substance
24 for which there is an approved new drug application, or (iv) with respect
25 to a particular person, any substance if an exemption is in effect for
26 investigational use for that person, under section 505 of the Federal
27 Food, Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
28 January 1, 2014, to the extent conduct with respect to such substance is
29 pursuant to such exemption;
30 (32) Anabolic steroid means any drug or hormonal substance,
31 chemically and pharmacologically related to testosterone (other than
-7-
LB431 LB431
2025 2025
1 estrogens, progestins, and corticosteroids), that promotes muscle growth
2 and includes any controlled substance in Schedule III(d) of section
3 28-405. Anabolic steroid does not include any anabolic steroid which is
4 expressly intended for administration through implants to cattle or other
5 nonhuman species and has been approved by the Secretary of Health and
6 Human Services for such administration, but if any person prescribes,
7 dispenses, or distributes such a steroid for human use, such person shall
8 be considered to have prescribed, dispensed, or distributed an anabolic
9 steroid within the meaning of this subdivision;
10 (33) Chart order means an order for a controlled substance issued by
11 a practitioner for a patient who is in the hospital where the chart is
12 stored or for a patient receiving detoxification treatment or maintenance
13 treatment pursuant to section 28-412. Chart order does not include a
14 prescription;
15 (34) Medical order means a prescription, a chart order, or an order
16 for pharmaceutical care issued by a practitioner;
17 (35) Prescription means an order for a controlled substance issued
18 by a practitioner. Prescription does not include a chart order;
19 (36) Registrant means any person who has a controlled substances
20 registration issued by the state or the Drug Enforcement Administration
21 of the United States Department of Justice;
22 (37) Reverse distributor means a person whose primary function is to
23 act as an agent for a pharmacy, wholesaler, manufacturer, or other entity
24 by receiving, inventorying, and managing the disposition of outdated,
25 expired, or otherwise nonsaleable controlled substances;
26 (38) Signature means the name, word, or mark of a person written in
27 his or her own hand with the intent to authenticate a writing or other
28 form of communication or a digital signature which complies with section
29 86-611 or an electronic signature;
30 (39) Facsimile means a copy generated by a system that encodes a
31 document or photograph into electrical signals, transmits those signals
-8-
LB431 LB431
2025 2025
1 over telecommunications lines, and reconstructs the signals to create an
2 exact duplicate of the original document at the receiving end;
3 (40) Electronic signature has the definition found in section
4 86-621;
5 (41) Electronic transmission means transmission of information in
6 electronic form. Electronic transmission includes computer-to-computer
7 transmission or computer-to-facsimile transmission;
8 (42) Long-term care facility means an intermediate care facility, an
9 intermediate care facility for persons with developmental disabilities, a
10 long-term care hospital, a mental health substance use treatment center,
11 a nursing facility, or a skilled nursing facility, as such terms are
12 defined in the Health Care Facility Licensure Act;
13 (43) Compounding has the same meaning as in section 38-2811;
14 (44) Cannabinoid receptor agonist means any chemical compound or
15 substance that, according to scientific or medical research, study,
16 testing, or analysis, demonstrates the presence of binding activity at
17 one or more of the CB1 or CB2 cell membrane receptors located within the
18 human body. Cannabinoid receptor agonist does not include cannabidiol
19 contained in a drug product approved by the federal Food and Drug
20 Administration; and
21 (45) Kratom means any product or ingredient containing:
22 (a) Any part of the leaf of the mitragyna speciosa plant if the
23 plant contains the alkaloid mitragynine or 7-hydroxymitragynine; or
24 (b) A synthetic material that contains the alkaloid mitragynine or
25 7-hydroxymitragynine; and
26 (46) (45) Lookalike substance means a product or substance, not
27 specifically designated as a controlled substance in section 28-405, that
28 is either portrayed in such a manner by a person to lead another person
29 to reasonably believe that it produces effects on the human body that
30 replicate, mimic, or are intended to simulate the effects produced by a
31 controlled substance or that possesses one or more of the following
-9-
LB431 LB431
2025 2025
1 indicia or characteristics:
2 (a) The packaging or labeling of the product or substance suggests
3 that the user will achieve euphoria, hallucination, mood enhancement,
4 stimulation, or another effect on the human body that replicates or
5 mimics those produced by a controlled substance;
6 (b) The name or packaging of the product or substance uses images or
7 labels suggesting that it is a controlled substance or produces effects
8 on the human body that replicate or mimic those produced by a controlled
9 substance;
10 (c) The product or substance is marketed or advertised for a
11 particular use or purpose and the cost of the product or substance is
12 disproportionately higher than other products or substances marketed or
13 advertised for the same or similar use or purpose;
14 (d) The packaging or label on the product or substance contains
15 words or markings that state or suggest that the product or substance is
16 in compliance with state and federal laws regulating controlled
17 substances;
18 (e) The owner or person in control of the product or substance uses
19 evasive tactics or actions to avoid detection or inspection of the
20 product or substance by law enforcement authorities;
21 (f) The owner or person in control of the product or substance makes
22 a verbal or written statement suggesting or implying that the product or
23 substance is a synthetic drug or that consumption of the product or
24 substance will replicate or mimic effects on the human body to those
25 effects commonly produced through use or consumption of a controlled
26 substance;
27 (g) The owner or person in control of the product or substance makes
28 a verbal or written statement to a prospective customer, buyer, or
29 recipient of the product or substance implying that the product or
30 substance may be resold for profit; or
31 (h) The product or substance contains a chemical or chemical
-10-
LB431 LB431
2025 2025
1 compound that does not have a legitimate relationship to the use or
2 purpose claimed by the seller, distributor, packer, or manufacturer of
3 the product or substance or indicated by the product name, appearing on
4 the product's packaging or label or depicted in advertisement of the
5 product or substance.
6 Sec. 2. Section 28-405, Revised Statutes Cumulative Supplement,
7 2024, is amended to read:
8 28-405 The following are the schedules of controlled substances
9 referred to in the Uniform Controlled Substances Act, unless specifically
10 contained on the list of exempted products of the Drug Enforcement
11 Administration of the United States Department of Justice as the list
12 existed on January 31, 2022:
13 Schedule I
14 (a) Any of the following opiates, including their isomers, esters,
15 ethers, salts, and salts of isomers, esters, and ethers, unless
16 specifically excepted, whenever the existence of such isomers, esters,
17 ethers, and salts is possible within the specific chemical designation:
18 (1) Acetylmethadol;
19 (2) Allylprodine;
20 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
21 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
22 (4) Alphameprodine;
23 (5) Alphamethadol;
24 (6) Benzethidine;
25 (7) Betacetylmethadol;
26 (8) Betameprodine;
27 (9) Betamethadol;
28 (10) Betaprodine;
29 (11) Clonitazene;
30 (12) Dextromoramide;
31 (13) Difenoxin;
-11-
LB431 LB431
2025 2025
1 (14) Diampromide;
2 (15) Diethylthiambutene;
3 (16) Dimenoxadol;
4 (17) Dimepheptanol;
5 (18) Dimethylthiambutene;
6 (19) Dioxaphetyl butyrate;
7 (20) Dipipanone;
8 (21) Ethylmethylthiambutene;
9 (22) Etonitazene;
10 (23) Etoxeridine;
11 (24) Furethidine;
12 (25) Hydroxypethidine;
13 (26) Ketobemidone;
14 (27) Levomoramide;
15 (28) Levophenacylmorphan;
16 (29) Morpheridine;
17 (30) Noracymethadol;
18 (31) Norlevorphanol;
19 (32) Normethadone;
20 (33) Norpipanone;
21 (34) Phenadoxone;
22 (35) Phenampromide;
23 (36) Phenomorphan;
24 (37) Phenoperidine;
25 (38) Piritramide;
26 (39) Proheptazine;
27 (40) Properidine;
28 (41) Propiram;
29 (42) Racemoramide;
30 (43) Trimeperidine;
31 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
-12-
LB431 LB431
2025 2025
1 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
2 piperidine;
3 (45) Tilidine;
4 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
5 phenylpropanamide, its optical and geometric isomers, salts, and salts of
6 isomers;
7 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
8 isomers, salts, and salts of isomers;
9 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
10 optical isomers, salts, and salts of isomers;
11 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
12 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
13 isomers;
14 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
16 of isomers;
17 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
18 its optical isomers, salts, and salts of isomers;
19 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
20 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
21 of isomers;
22 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
23 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
24 geometric isomers, salts, and salts of isomers;
25 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
26 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
27 salts, and salts of isomers;
28 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
29 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
30 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
31 propanamide, its optical isomers, salts, and salts of isomers;
-13-
LB431 LB431
2025 2025
1 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
2 piperidinyl)propanamide, its optical isomers, salts, and salts of
3 isomers;
4 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
5 methylbenzamide;
6 (59) 4-Fluoroisobutyryl Fentanyl;
7 (60) Acetyl Fentanyl;
8 (61) Acyrloylfentanyl;
9 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
10 benzamide;
11 (63) Butyryl fentanyl;
12 (64) Cyclopentyl fentanyl;
13 (65) Cyclopropyl fentanyl;
14 (66) Furanyl fentanyl;
15 (67) Isobutyryl fentanyl;
16 (68) Isotonitazene;
17 (69) Methoxyacetyl fentanyl;
18 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
19 (71) Tetrahydrofuranyl fentanyl;
20 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
21 yl) propionamide;
22 (73) Ocfentanil;
23 (74) Ortho-Fluorofentanyl;
24 (75) Para-chloroisobutyryl fentanyl;
25 (76) Para-Fluorobutyryl Fentanyl;
26 (77) Valeryl fentanyl;
27 (78) Phenyl Fentanyl;
28 (79) Para-Methylfentanyl;
29 (80) Thiofuranyl Fentanyl;
30 (81) Beta-methyl Fentanyl;
31 (82) Beta'-Phenyl Fentanyl;
-14-
LB431 LB431
2025 2025
1 (83) Crotonyl Fentanyl;
2 (84) 2'-Fluoro Ortho-Fluorofentanyl;
3 (85) 4'-Methyl Acetyl Fentanyl;
4 (86) Ortho-Fluorobutyryl Fentanyl;
5 (87) Ortho-Methyl Acetylfentanyl;
6 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
7 (89) Ortho-Fluoroacryl Fentanyl;
8 (90) Fentanyl Carbamate;
9 (91) Ortho-Fluoroisobutyryl Fentanyl;
10 (92) Para-Fluoro Furanyl Fentanyl;
11 (93) Para-Methoxybutyryl Fentanyl;
12 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
13 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
14 (95) Fentanyl-related substances, their isomers, esters, ethers,
15 salts and salts of isomers, esters, and ethers. Unless specifically
16 excepted, listed in another schedule, or specifically named in this
17 schedule, this includes any substance that is structurally related to
18 fentanyl by one or more of the following modifications:
19 (A) Replacement of the phenyl portion of the phenethyl group by any
20 monocycle, whether or not further substituted in or on the monocycle;
21 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
22 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
23 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
24 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
25 (D) Replacement of the aniline ring with any aromatic monocycle
26 whether or not further substituted in or on the aromatic monocycle; or
27 (E) Replacement of the N-propionyl group by another acyl group.
28 (b) Any of the following opium derivatives, their salts, isomers,
29 and salts of isomers, unless specifically excepted, whenever the
30 existence of such salts, isomers, and salts of isomers is possible within
31 the specific chemical designation:
-15-
LB431 LB431
2025 2025
1 (1) Acetorphine;
2 (2) Acetyldihydrocodeine;
3 (3) Benzylmorphine;
4 (4) Codeine methylbromide;
5 (5) Codeine-N-Oxide;
6 (6) Cyprenorphine;
7 (7) Desomorphine;
8 (8) Dihydromorphine;
9 (9) Drotebanol;
10 (10) Etorphine, except hydrochloride salt;
11 (11) Heroin;
12 (12) Hydromorphinol;
13 (13) Methyldesorphine;
14 (14) Methyldihydromorphine;
15 (15) Morphine methylbromide;
16 (16) Morphine methylsulfonate;
17 (17) Morphine-N-Oxide;
18 (18) Myrophine;
19 (19) Nicocodeine;
20 (20) Nicomorphine;
21 (21) Normorphine;
22 (22) Pholcodine; and
23 (23) Thebacon.
24 (c) Any material, compound, mixture, or preparation which contains
25 any quantity of the following hallucinogenic substances, their salts,
26 isomers, and salts of isomers, unless specifically excepted, whenever the
27 existence of such salts, isomers, and salts of isomers is possible within
28 the specific chemical designation, and, for purposes of this subdivision
29 only, isomer shall include the optical, position, and geometric isomers:
30 (1) Bufotenine. Trade and other names shall include, but are not
31 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
-16-
LB431 LB431
2025 2025
1 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
2 dimethyltryptamine; and mappine;
3 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
4 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
5 methylphenethylamine; and 4-bromo-2,5-DMA;
6 (3) 4-methoxyamphetamine. Trade and other names shall include, but
7 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
8 paramethoxyamphetamine, PMA;
9 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
10 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
11 methylphenethylamine; DOM; and STP;
12 (5) Para-methoxymethamphetamine. Trade and other names shall
13 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
14 amine, PMMA, and 4-MMA;
15 (6) Ibogaine. Trade and other names shall include, but are not
16 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
17 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
18 iboga;
19 (7) Lysergic acid diethylamide;
20 (8) Marijuana;
21 (9) Mescaline;
22 (10) Methoxetamine (MXE);
23 (11) Peyote. Peyote shall mean all parts of the plant presently
24 classified botanically as Lophophora williamsii Lemaire, whether growing
25 or not, the seeds thereof, any extract from any part of such plant, and
26 every compound, manufacture, salts, derivative, mixture, or preparation
27 of such plant or its seeds or extracts;
28 (12) Psilocybin;
29 (13) Psilocyn;
30 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
31 equivalents of the substances contained in the plant or in the resinous
-17-
LB431 LB431
2025 2025
1 extractives of cannabis, sp. or synthetic substances, derivatives, and
2 their isomers with similar chemical structure and pharmacological
3 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
4 and their optical isomers, excluding dronabinol in a drug product
5 approved by the federal Food and Drug Administration; Delta 6 cis or
6 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
7 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
8 of these substances is not internationally standardized, compounds of
9 these structures shall be included regardless of the numerical
10 designation of atomic positions covered. Tetrahydrocannabinols does not
11 include cannabidiol contained in a drug product approved by the federal
12 Food and Drug Administration;
13 (15) N-ethyl-3-piperidyl benzilate;
14 (16) N-methyl-3-piperidyl benzilate;
15 (17) Thiophene analog of phencyclidine. Trade and other names shall
16 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
17 2-thienyl analog of phencyclidine; TPCP; and TCP;
18 (18) Hashish or concentrated cannabis;
19 (19) Parahexyl. Trade and other names shall include, but are not
20 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
21 dibenzo(b,d)pyran; and Synhexyl;
22 (20) Ethylamine analog of phencyclidine. Trade and other names shall
23 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
24 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
25 cyclohexamine; and PCE;
26 (21) Pyrrolidine analog of phencyclidine. Trade and other names
27 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
28 pyrrolidine; PCPy; and PHP;
29 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
30 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
31 alpha-ET; and AET;
-18-
LB431 LB431
2025 2025
1 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
2 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
3 (25) Alpha-methyltryptamine, which is also known as AMT;
4 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
5 Salvinorin A includes all parts of the plant presently classified
6 botanically as Salvia divinorum, whether growing or not, the seeds
7 thereof, any extract from any part of such plant, and every compound,
8 manufacture, derivative, mixture, or preparation of such plant, its
9 seeds, or its extracts, including salts, isomers, and salts of isomers
10 whenever the existence of such salts, isomers, and salts of isomers is
11 possible within the specific chemical designation;
12 (27) Any material, compound, mixture, or preparation containing any
13 quantity of synthetically produced cannabinoids as listed in subdivisions
14 (A) through (L) of this subdivision, including their salts, isomers,
15 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
16 unless specifically excepted elsewhere in this section. Since
17 nomenclature of these synthetically produced cannabinoids is not
18 internationally standardized and may continually evolve, these structures
19 or compounds of these structures shall be included under this
20 subdivision, regardless of their specific numerical designation of atomic
21 positions covered, so long as it can be determined through a recognized
22 method of scientific testing or analysis that the substance contains
23 properties that fit within one or more of the following categories:
24 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
25 contained in a plant of the genus cannabis (cannabis plant), as well as
26 synthetic equivalents of the substances contained in the plant, or in the
27 resinous extractives of cannabis, sp. and/or synthetic substances,
28 derivatives, and their isomers with similar chemical structure and
29 pharmacological activity such as the following: Delta 1 cis or trans
30 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
31 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
-19-
LB431 LB431
2025 2025
1 tetrahydrocannabinol, and its optical isomers. This subdivision does not
2 include cannabidiol contained in a drug product approved by the federal
3 Food and Drug Administration;
4 (B) Naphthoylindoles: Any compound containing a 3-(1-
5 naphthoyl)indole structure with substitution at the nitrogen atom of the
6 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
7 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
8 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
9 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
10 tetrahydropyranylmethyl group, whether or not further substituted in or
11 on any of the listed ring systems to any extent;
12 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
13 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
14 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
15 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
16 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
17 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
18 tetrahydropyranylmethyl group, whether or not further substituted in or
19 on any of the listed ring systems to any extent;
20 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
21 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
22 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
23 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
24 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
25 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
26 tetrahydropyranylmethyl group, whether or not further substituted in or
27 on any of the listed ring systems to any extent;
28 (E) Naphthylideneindenes: Any compound containing a
29 naphthylideneindene structure with substitution at the 3-position of the
30 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
31 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
-20-
LB431 LB431
2025 2025
1 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
2 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
3 tetrahydropyranylmethyl group, whether or not further substituted in or
4 on any of the listed ring systems to any extent;
5 (F) Phenylacetylindoles: Any compound containing a 3-
6 phenylacetylindole structure with substitution at the nitrogen atom of
7 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
8 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
9 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
10 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
11 tetrahydropyranylmethyl group, whether or not further substituted in or
12 on any of the listed ring systems to any extent;
13 (G) Cyclohexylphenols: Any compound containing a 2-(3-
14 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
15 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
16 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
17 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
18 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
19 tetrahydropyranylmethyl group, whether or not substituted in or on any of
20 the listed ring systems to any extent;
21 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
22 structure with substitution at the nitrogen atom of the indole ring by an
23 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
24 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
25 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
26 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
27 further substituted in or on any of the listed ring systems to any
28 extent;
29 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
30 structure with substitution at the nitrogen atom of the indole ring by an
31 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
-21-
LB431 LB431
2025 2025
1 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
2 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
3 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
4 further substituted in or on any of the listed ring systems to any
5 extent;
6 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
7 tetramethylcyclopropanoylindole structure with substitution at the
8 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
9 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
10 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
12 tetrahydropyranylmethyl group, whether or not further substituted in or
13 on any of the listed ring systems to any extent;
14 (K) Indole carboxamides: Any compound containing a 1-indole-3-
15 carboxamide structure with substitution at the nitrogen atom of the
16 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
17 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
18 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
19 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
20 tetrahydropyranylmethyl group, substitution at the carboxamide group by
21 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
22 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
23 substituted in or on any of the listed ring systems to any extent or to
24 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
25 propionaldehyde groups to any extent;
26 (L) Indole carboxylates: Any compound containing a 1-indole-3-
27 carboxylate structure with substitution at the nitrogen atom of the
28 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
29 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
30 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
31 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
-22-
LB431 LB431
2025 2025
1 tetrahydropyranylmethyl group, substitution at the carboxylate group by
2 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
3 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
4 substituted in or on any of the listed ring systems to any extent or to
5 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
6 propionaldehyde groups to any extent; and
7 (M) Any nonnaturally occurring substance, chemical compound,
8 mixture, or preparation, not specifically listed elsewhere in these
9 schedules and which is not approved for human consumption by the federal
10 Food and Drug Administration, containing or constituting a cannabinoid
11 receptor agonist as defined in section 28-401;
12 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
13 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
14 and salts of isomers, esters, and ethers, whenever the existence of such
15 isomers, esters, ethers, and salts is possible within the specific
16 chemical designation;
17 (29) Any material, compound, mixture, or preparation containing any
18 quantity of a substituted phenethylamine as listed in subdivisions (A)
19 through (C) of this subdivision, unless specifically excepted, listed in
20 another schedule, or specifically named in this schedule, that is
21 structurally derived from phenylethan-2-amine by substitution on the
22 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
23 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
24 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
25 or tetrahydropyran ring system; or by substitution with two fused ring
26 systems from any combination of the furan, tetrahydrofuran, or
27 tetrahydropyran ring systems, whether or not the compound is further
28 modified in any of the following ways:
29 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
30 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
31 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
-23-
LB431 LB431
2025 2025
1 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
2 and including, but not limited to:
3 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
4 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
5 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
6 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
7 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
8 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
9 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
10 or 2,5-Dimethoxyphenethylamine;
11 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
12 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
13 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
14 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
15 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
16 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
17 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
18 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
19 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
20 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
21 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
22 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
23 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
24 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
25 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
26 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
27 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
28 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
29 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
30 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
31 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
-24-
LB431 LB431
2025 2025
1 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
2 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
3 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
4 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
5 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
6 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
7 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
8 methoxybenzyl)phenethylamine;
9 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
10 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
11 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
12 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
13 which is also known as 2CB-5-hemiFLY;
14 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
15 yl)ethanamine, which is also known as 2C-B-FLY;
16 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
17 yl)ethanamine, which is also known as 2C-B-butterFLY;
18 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
19 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
20 NBOMe;
21 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
22 which is also known as bromo-benzodifuranylisopropylamine or bromo-
23 dragonFLY;
24 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
25 is also known as 2C-INBOH or 25I-NBOH;
26 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
27 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
28 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
29 as 5-APDB;
30 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
31 known as 6-APDB;
-25-
LB431 LB431
2025 2025
1 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
2 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
3 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
4 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
5 known as 2C-T-7;
6 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
7 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
8 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
9 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
10 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
11 MDMA;
12 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
13 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
14 (xxxvii) 3,4,5-trimethoxy amphetamine; and
15 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
16 is also known as N-hydroxyMDA;
17 (30) Any material, compound, mixture, or preparation containing any
18 quantity of a substituted tryptamine unless specifically excepted, listed
19 in another schedule, or specifically named in this schedule, that is
20 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
21 known as tryptamine, by mono- or di-substitution of the amine nitrogen
22 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
23 in a cyclic structure whether or not the compound is further substituted
24 at the alpha position with an alkyl group or whether or not further
25 substituted on the indole ring to any extent with any alkyl, alkoxy,
26 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
27 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
28 DALT;
29 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
30 DMT or OAcetylpsilocin;
31 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
-26-
LB431 LB431
2025 2025
1 HO-MET;
2 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
3 HO-DIPT;
4 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
5 5-MeOMiPT;
6 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
7 DMT;
8 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
9 MeO-DiPT;
10 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
11 DET; and
12 (I) Dimethyltryptamine, which is also known as DMT; and
13 (31)(A) Any substance containing any quantity of the following
14 materials, compounds, mixtures, or structures:
15 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
16 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
17 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
18 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
19 (v) Fluoromethcathinone, or FMC;
20 (vi) Naphthylpyrovalerone, or naphyrone; or
21 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
22 butylone; or
23 (B) Unless listed in another schedule, any substance which contains
24 any quantity of any material, compound, mixture, or structure, other than
25 bupropion, that is structurally derived by any means from 2-
26 aminopropan-1-one by substitution at the 1-position with either phenyl,
27 naphthyl, or thiophene ring systems, whether or not the compound is
28 further modified in any of the following ways:
29 (i) Substitution in the ring system to any extent with alkyl,
30 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
31 whether or not further substituted in the ring system by one or more
-27-
LB431 LB431
2025 2025
1 other univalent substituents;
2 (ii) Substitution at the 3-position with an acyclic alkyl
3 substituent; or
4 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
5 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
6 structure.
7 (d) Unless specifically excepted or unless listed in another
8 schedule, any material, compound, mixture, or preparation which contains
9 any quantity of the following substances having a depressant effect on
10 the central nervous system, including its salts, isomers, and salts of
11 isomers whenever the existence of such salts, isomers, and salts of
12 isomers is possible within the specific chemical designation:
13 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
14 yl)amino]heptanoic acid, including its salts, isomers, and salts of
15 isomers;
16 (2) Mecloqualone;
17 (3) Methaqualone; and
18 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
19 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
20 Oxybate; and Sodium Oxybutyrate.
21 (e) Unless specifically excepted or unless listed in another
22 schedule, any material, compound, mixture, or preparation which contains
23 any quantity of the following substances having a stimulant effect on the
24 central nervous system, including its salts, isomers, and salts of
25 isomers:
26 (1) Fenethylline;
27 (2) N-ethylamphetamine;
28 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
29 dihydro-5-phenyl-2-oxazolamine;
30 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
31 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
-28-
LB431 LB431
2025 2025
1 (5) Methcathinone, its salts, optical isomers, and salts of optical
2 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
3 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
4 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
5 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
6 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
7 phenyl-2-oxazolamine;
8 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
9 and N,N-alpha-trimethylphenethylamine;
10 (8) Benzylpiperazine, 1-benzylpiperazine;
11 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
12 methyl-5-(4-methylphenyl)-2-oxazolamine); and
13 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
14 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
15 isomers.
16 (f) Kratom.
17 (g) (f) Any controlled substance analogue to the extent intended for
18 human consumption.
19 Schedule II
20 (a) Any of the following substances except those narcotic drugs
21 listed in other schedules whether produced directly or indirectly by
22 extraction from substances of vegetable origin, independently by means of
23 chemical synthesis, or by combination of extraction and chemical
24 synthesis:
25 (1) Opium and opiate, and any salt, compound, derivative, or
26 preparation of opium or opiate, excluding apomorphine, buprenorphine,
27 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
28 naloxone, and naltrexone and their salts, but including the following:
29 (A) Raw opium;
30 (B) Opium extracts;
31 (C) Opium fluid;
-29-
LB431 LB431
2025 2025
1 (D) Powdered opium;
2 (E) Granulated opium;
3 (F) Tincture of opium;
4 (G) Codeine;
5 (H) Ethylmorphine;
6 (I) Etorphine hydrochloride;
7 (J) Hydrocodone;
8 (K) Hydromorphone;
9 (L) Metopon;
10 (M) Morphine;
11 (N) Oxycodone;
12 (O) Oxymorphone;
13 (P) Oripavine;
14 (Q) Thebaine; and
15 (R) Dihydroetorphine;
16 (2) Any salt, compound, derivative, or preparation thereof which is
17 chemically equivalent to or identical with any of the substances referred
18 to in subdivision (1) of this subdivision, except that these substances
19 shall not include the isoquinoline alkaloids of opium;
20 (3) Opium poppy and poppy straw;
21 (4) Coca leaves and any salt, compound, derivative, or preparation
22 of coca leaves, and any salt, compound, derivative, or preparation
23 thereof which is chemically equivalent to or identical with any of these
24 substances, including cocaine or ecgonine and its salts, optical isomers,
25 and salts of optical isomers, except that the substances shall not
26 include decocainized coca leaves or extractions which do not contain
27 cocaine or ecgonine; and
28 (5) Concentrate of poppy straw, the crude extract of poppy straw in
29 either liquid, solid, or powder form which contains the phenanthrene
30 alkaloids of the opium poppy.
31 (b) Unless specifically excepted or unless in another schedule any
-30-
LB431 LB431
2025 2025
1 of the following opiates, including their isomers, esters, ethers, salts,
2 and salts of their isomers, esters, and ethers whenever the existence of
3 such isomers, esters, ethers, and salts is possible within the specific
4 chemical designation, dextrorphan excepted:
5 (1) Alphaprodine;
6 (2) Anileridine;
7 (3) Bezitramide;
8 (4) Diphenoxylate;
9 (5) Fentanyl;
10 (6) Isomethadone;
11 (7) Levomethorphan;
12 (8) Levorphanol;
13 (9) Metazocine;
14 (10) Methadone;
15 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
16 butane;
17 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
18 diphenylpropane-carboxylic acid;
19 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
20 (14) Oliceridine;
21 (15) Pethidine or meperidine;
22 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
23 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
24 carboxylate;
25 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
26 carboxylic acid;
27 (19) Phenazocine;
28 (20) Piminodine;
29 (21) Racemethorphan;
30 (22) Racemorphan;
31 (23) Dihydrocodeine;
-31-
LB431 LB431
2025 2025
1 (24) Bulk Propoxyphene in nondosage forms;
2 (25) Sufentanil;
3 (26) Alfentanil;
4 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
5 acetylmethadol, levomethadyl acetate, and LAAM;
6 (28) Carfentanil;
7 (29) Remifentanil;
8 (30) Tapentadol; and
9 (31) Thiafentanil.
10 (c) Any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a potential for abuse
12 associated with a stimulant effect on the central nervous system:
13 (1) Amphetamine, its salts, optical isomers, and salts of its
14 optical isomers;
15 (2) Phenmetrazine and its salts;
16 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
17 (4) Methylphenidate; and
18 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
19 (d) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substances having a potential for abuse
21 associated with a depressant effect on the central nervous system,
22 including their salts, isomers, and salts of isomers whenever the
23 existence of such salts, isomers, and salts of isomers is possible within
24 the specific chemical designations:
25 (1) Amobarbital;
26 (2) Secobarbital;
27 (3) Pentobarbital;
28 (4) Phencyclidine; and
29 (5) Glutethimide.
30 (e) Hallucinogenic substances known as:
31 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
-32-
LB431 LB431
2025 2025
1 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
2 dibenzo(b,d)pyran-9-one; and
3 (2) Dronabinol in an oral solution in a drug product approved by the
4 federal Food and Drug Administration.
5 (f) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances:
8 (1) Immediate precursor to amphetamine and methamphetamine:
9 Phenylacetone. Trade and other names shall include, but are not limited
10 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
11 ketone;
12 (2) Immediate precursors to phencyclidine, PCP:
13 (A) 1-phenylcyclohexylamine; or
14 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
15 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
16 (ANPP).
17 Schedule III
18 (a) Any material, compound, mixture, or preparation which contains
19 any quantity of the following substances having a potential for abuse
20 associated with a stimulant effect on the central nervous system,
21 including their salts, isomers, whether optical, position, or geometric,
22 and salts of such isomers whenever the existence of such salts, isomers,
23 and salts of isomers is possible within the specific chemical
24 designation:
25 (1) Benzphetamine;
26 (2) Chlorphentermine;
27 (3) Clortermine; and
28 (4) Phendimetrazine.
29 (b) Any material, compound, mixture, or preparation which contains
30 any quantity of the following substances having a potential for abuse
31 associated with a depressant effect on the central nervous system:
-33-
LB431 LB431
2025 2025
1 (1) Any substance which contains any quantity of a derivative of
2 barbituric acid or any salt of a derivative of barbituric acid, except
3 those substances which are specifically listed in other schedules of this
4 section;
5 (2) Aprobarbital;
6 (3) Butabarbital;
7 (4) Butalbital;
8 (5) Butethal;
9 (6) Butobarbital;
10 (7) Chlorhexadol;
11 (8) Embutramide;
12 (9) Lysergic acid;
13 (10) Lysergic acid amide;
14 (11) Methyprylon;
15 (12) Perampanel;
16 (13) Secbutabarbital;
17 (14) Sulfondiethylmethane;
18 (15) Sulfonethylmethane;
19 (16) Sulfonmethane;
20 (17) Nalorphine;
21 (18) Talbutal;
22 (19) Thiamylal;
23 (20) Thiopental;
24 (21) Vinbarbital;
25 (22) Any compound, mixture, or preparation containing amobarbital,
26 secobarbital, pentobarbital, or any salt thereof and one or more other
27 active medicinal ingredients which are not listed in any schedule;
28 (23) Any suppository dosage form containing amobarbital,
29 secobarbital, pentobarbital, or any salt of any of these drugs and
30 approved by the federal Food and Drug Administration for marketing only
31 as a suppository;
-34-
LB431 LB431
2025 2025
1 (24) Any drug product containing gamma-hydroxybutyric acid,
2 including its salts, isomers, and salts of isomers, for which an
3 application is approved under section 505 of the Federal Food, Drug, and
4 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
5 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
6 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
7 cyclohexanone; and
8 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
9 names for a tiletamine-zolazepam combination product shall include, but
10 are not limited to: telazol. Trade or other names for tiletamine shall
11 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
12 cyclohexanone. Trade or other names for zolazepam shall include, but are
13 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
14 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
15 (c) Unless specifically excepted or unless listed in another
16 schedule:
17 (1) Any material, compound, mixture, or preparation containing
18 limited quantities of any of the following narcotic drugs, or any salts
19 calculated as the free anhydrous base or alkaloid, in limited quantities
20 as set forth below:
21 (A) Not more than one and eight-tenths grams of codeine per one
22 hundred milliliters or not more than ninety milligrams per dosage unit,
23 with an equal or greater quantity of an isoquinoline alkaloid of opium;
24 (B) Not more than one and eight-tenths grams of codeine per one
25 hundred milliliters or not more than ninety milligrams per dosage unit,
26 with one or more active, nonnarcotic ingredients in recognized
27 therapeutic amounts;
28 (C) Not more than one and eight-tenths grams of dihydrocodeine per
29 one hundred milliliters or not more than ninety milligrams per dosage
30 unit, with one or more active, nonnarcotic ingredients in recognized
31 therapeutic amounts;
-35-
LB431 LB431
2025 2025
1 (D) Not more than three hundred milligrams of ethylmorphine per one
2 hundred milliliters or not more than fifteen milligrams per dosage unit,
3 with one or more active, nonnarcotic ingredients in recognized
4 therapeutic amounts;
5 (E) Not more than five hundred milligrams of opium per one hundred
6 milliliters or per one hundred grams, or not more than twenty-five
7 milligrams per dosage unit, with one or more active, nonnarcotic
8 ingredients in recognized therapeutic amounts; and
9 (F) Not more than fifty milligrams of morphine per one hundred
10 milliliters or per one hundred grams with one or more active, nonnarcotic
11 ingredients in recognized therapeutic amounts; and
12 (2) Any material, compound, mixture, or preparation containing any
13 of the following narcotic drug or its salts, as set forth below:
14 (A) Buprenorphine.
15 (d) Unless contained on the list of exempt anabolic steroids of the
16 Drug Enforcement Administration of the United States Department of
17 Justice as the list existed on January 31, 2022, any anabolic steroid,
18 which shall include any material, compound, mixture, or preparation
19 containing any quantity of the following substances, including its salts,
20 isomers, and salts of isomers whenever the existence of such salts of
21 isomers is possible within the specific chemical designation:
22 (1) 3-beta,17-dihydroxy-5a-androstane;
23 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
24 (3) 5-alpha-androstan-3,17-dione;
25 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
26 ene);
27 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
28 ene);
29 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
30 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
31 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
-36-
LB431 LB431
2025 2025
1 (9) 4-androstenedione (androst-4-en-3,17-dione);
2 (10) 5-androstenedione (androst-5-en-3,17-dione);
3 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
4 hydroxyandrost-4-en-3-one);
5 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
6 (13) Boldione (androsta-1,4-diene-3,17-3-one);
7 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
8 en-3-one);
9 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
10 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
11 alpha-methyl-androst-1,4-dien-3-one);
12 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
13 en-17-beta-ol) (a.k.a. 'madol');
14 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
15 hydroxy-5-alpha-androst-1-en-3-one);
16 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
17 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
18 androstan-3-one);
19 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
20 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
21 dihydroxyandrost-4-en-3-one);
22 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
23 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
24 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
25 furazan);
26 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
27 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
28 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
29 one);
30 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
31 one);
-37-
LB431 LB431
2025 2025
1 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
2 one);
3 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
4 dien-3-one);
5 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
6 ene);
7 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
8 beta-ol-3-one);
9 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
10 one);
11 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
12 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
13 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
14 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
15 hydroxy-17-beta-hydroxyestr-4-en-3-one);
16 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
17 dien-3-one);
18 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
19 trien-3-one);
20 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
21 en-3-one);
22 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
23 en-3-one);
24 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
25 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
26 methyl-1-testosterone');
27 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
28 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
29 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
30 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
31 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
-38-
LB431 LB431
2025 2025
1 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
2 dione);
3 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
4 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
5 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
6 en-3-one);
7 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
8 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
9 one);
10 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
11 one);
12 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
13 androstan-3-one);
14 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
15 en-3-one);
16 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
17 hydroxy-[5-alpha]-androstan-3-one);
18 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
19 c]pyrazole);
20 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
21 androst-2-eno[3,2-c]-pyrazole);
22 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
23 one);
24 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
25 oic acid lactone);
26 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
27 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
28 hydroxygon-4,9,11-trien-3-one);
29 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
30 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
31 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
-39-
LB431 LB431
2025 2025
1 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
2 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
3 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
4 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
5 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
6 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
7 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
8 beta-ol;
9 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
10 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
11 dione;
12 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
13 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
14 (78) 4-hydroxy-androst-4-ene-3,17-dione;
15 (79) 5 alpha-Androstan-3,6,17-trione;
16 (80) 6-bromo-androst-1,4-diene-3,17-dione;
17 (81) 6-bromo-androstan-3,17-dione;
18 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
19 (83) Delta 1-dihydrotestosterone;
20 (84) Estra-4,9,11-triene-3,17-dione; and
21 (85) Any salt, ester, or ether of a drug or substance described or
22 listed in this subdivision if the salt, ester, or ether promotes muscle
23 growth.
24 (e) Hallucinogenic substances known as:
25 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
26 gelatin capsule in a drug product approved by the federal Food and Drug
27 Administration. Some other names for dronabinol are (6aR-
28 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
29 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
30 Schedule IV
31 (a) Any material, compound, mixture, or preparation which contains
-40-
LB431 LB431
2025 2025
1 any quantity of the following substances, including their salts, isomers,
2 and salts of isomers whenever the existence of such salts, isomers, and
3 salts of isomers is possible within the specific chemical designation:
4 (1) Barbital;
5 (2) Chloral betaine;
6 (3) Chloral hydrate;
7 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
8 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
9 water soluble esterified estrogens);
10 (5) Clonazepam;
11 (6) Clorazepate;
12 (7) Daridorexant;
13 (8) Diazepam;
14 (9) Ethchlorvynol;
15 (10) Ethinamate;
16 (11) Flurazepam;
17 (12) Mebutamate;
18 (13) Meprobamate;
19 (14) Methohexital;
20 (15) Methylphenobarbital;
21 (16) Oxazepam;
22 (17) Paraldehyde;
23 (18) Petrichloral;
24 (19) Phenobarbital;
25 (20) Prazepam;
26 (21) Alprazolam;
27 (22) Bromazepam;
28 (23) Camazepam;
29 (24) Clobazam;
30 (25) Clotiazepam;
31 (26) Cloxazolam;
-41-
LB431 LB431
2025 2025
1 (27) Delorazepam;
2 (28) Estazolam;
3 (29) Ethyl loflazepate;
4 (30) Fludiazepam;
5 (31) Flunitrazepam;
6 (32) Halazepam;
7 (33) Haloxazolam;
8 (34) Ketazolam;
9 (35) Loprazolam;
10 (36) Lorazepam;
11 (37) Lormetazepam;
12 (38) Medazepam;
13 (39) Nimetazepam;
14 (40) Nitrazepam;
15 (41) Nordiazepam;
16 (42) Oxazolam;
17 (43) Pinazepam;
18 (44) Temazepam;
19 (45) Tetrazepam;
20 (46) Triazolam;
21 (47) Midazolam;
22 (48) Quazepam;
23 (49) Zolpidem;
24 (50) Dichloralphenazone;
25 (51) Zaleplon;
26 (52) Zopiclone;
27 (53) Fospropofol;
28 (54) Alfaxalone;
29 (55) Suvorexant;
30 (56) Carisoprodol;
31 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
-42-
LB431 LB431
2025 2025
1 (58) Lemborexant;
2 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
3 (60) Remimazolam; and
4 (61) Serdexmethylphenidate.
5 (b) Any material, compound, mixture, or preparation which contains
6 any quantity of the following substance, including its salts, isomers,
7 whether optical, position, or geometric, and salts of such isomers,
8 whenever the existence of such salts, isomers, and salts of isomers is
9 possible: Fenfluramine.
10 (c) Unless specifically excepted or unless listed in another
11 schedule, any material, compound, mixture, or preparation which contains
12 any quantity of the following substances having a stimulant effect on the
13 central nervous system, including their salts, isomers, whether optical,
14 position, or geometric, and salts of such isomers whenever the existence
15 of such salts, isomers, and salts of isomers is possible within the
16 specific chemical designation:
17 (1) Diethylpropion;
18 (2) Phentermine;
19 (3) Pemoline, including organometallic complexes and chelates
20 thereof;
21 (4) Mazindol;
22 (5) Pipradrol;
23 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
24 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
25 (8) Fencamfamin;
26 (9) Fenproporex;
27 (10) Mefenorex;
28 (11) Modafinil; and
29 (12) Sibutramine.
30 (d) Unless specifically excepted or unless listed in another
31 schedule, any material, compound, mixture, or preparation which contains
-43-
LB431 LB431
2025 2025
1 any quantity of the following narcotic drugs, or their salts or isomers
2 calculated as the free anhydrous base or alkaloid, in limited quantities
3 as set forth below:
4 (1) Propoxyphene in manufactured dosage forms;
5 (2) Not more than one milligram of difenoxin and not less than
6 twenty-five micrograms of atropine sulfate per dosage unit; and
7 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
8 salts, optical and geometric isomers, and salts of these isomers to
9 include: Tramadol.
10 (e) Unless specifically excepted or unless listed in another
11 schedule, any material, compound, mixture, or preparation which contains
12 any quantity of the following substances substance, including their its
13 salts:
14 (1) Pentazocine; and
15 (2) Butorphanol (including its optical isomers).
16 (f) Any material, compound, mixture, or preparation which contains
17 any quantity of the following substance substances, including its salts,
18 isomers, and salts of such isomers, whenever the existence of such salts,
19 isomers, and salts of isomers is possible: Lorcaserin.
20 (g)(1) Unless specifically excepted or unless listed in another
21 schedule, any material, compound, mixture, or preparation which contains
22 any quantity of the following substance, including its salts, optical
23 isomers, and salts of such optical isomers: Ephedrine.
24 (2) The following drug products containing ephedrine, its salts,
25 optical isomers, and salts of such optical isomers, are excepted from
26 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
27 counter, in an area not accessible to customers, or in a locked case so
28 that a customer needs assistance from an employee to access the drug
29 product; (B) are sold by a person, eighteen years of age or older, in the
30 course of his or her employment to a customer eighteen years of age or
31 older with the following restrictions: No customer shall be allowed to
-44-
LB431 LB431
2025 2025
1 purchase, receive, or otherwise acquire more than three and six-tenths
2 grams of ephedrine base during a twenty-four-hour period; no customer
3 shall purchase, receive, or otherwise acquire more than nine grams of
4 ephedrine base during a thirty-day period; and the customer shall display
5 a valid driver's or operator's license, a Nebraska state identification
6 card, a military identification card, an alien registration card, or a
7 passport as proof of identification; (C) are labeled and marketed in a
8 manner consistent with the pertinent OTC Tentative Final or Final
9 Monograph; (D) are manufactured and distributed for legitimate medicinal
10 use in a manner that reduces or eliminates the likelihood of abuse; and
11 (E) are not marketed, advertised, or represented in any manner for the
12 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
13 high, heightened sexual performance, or increased muscle mass:
14 (i) Primatene Tablets; and
15 (ii) Bronkaid Dual Action Caplets.
16 Schedule V
17 (a) Any compound, mixture, or preparation containing any of the
18 following limited quantities of narcotic drugs or salts calculated as the
19 free anhydrous base or alkaloid, which shall include one or more
20 nonnarcotic active medicinal ingredients in sufficient proportion to
21 confer upon the compound, mixture, or preparation valuable medicinal
22 qualities other than those possessed by the narcotic drug alone:
23 (1) Not more than two hundred milligrams of codeine per one hundred
24 milliliters or per one hundred grams;
25 (2) Not more than one hundred milligrams of dihydrocodeine per one
26 hundred milliliters or per one hundred grams;
27 (3) Not more than one hundred milligrams of ethylmorphine per one
28 hundred milliliters or per one hundred grams;
29 (4) Not more than two and five-tenths milligrams of diphenoxylate
30 and not less than twenty-five micrograms of atropine sulfate per dosage
31 unit;
-45-
LB431 LB431
2025 2025
1 (5) Not more than one hundred milligrams of opium per one hundred
2 milliliters or per one hundred grams; and
3 (6) Not more than five-tenths milligram of difenoxin and not less
4 than twenty-five micrograms of atropine sulfate per dosage unit.
5 (b) Unless specifically exempted or excluded or unless listed in
6 another schedule, any material, compound, mixture, or preparation which
7 contains any quantity of the following substances having a stimulant
8 effect on the central nervous system, including its salts, isomers, and
9 salts of isomers: Pyrovalerone.
10 (c) Unless specifically exempted or excluded or unless listed in
11 another schedule, any material, compound, mixture, or preparation which
12 contains any quantity of the following substances having a depressant
13 effect on the central nervous system, including its salts, isomers, and
14 salts of isomers:
15 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
16 acid ethyl ester);
17 (2) Ganaxolone;
18 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
19 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
20 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
21 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
22 salts;
23 (6) Cenobamate; and
24 (7) Lasmiditan.
25 Sec. 3. Original sections 28-401 and 28-405, Revised Statutes
26 Cumulative Supplement, 2024, are repealed.
-46-
[DELETED: yLAa s 2 a 2 R S CSdB1L52]
[DELETED: S 1 S 2 R S C S22c( A m t d a a c s bi i i o a o m t t b o p(d o a p b d n i a c o c0c1k2(3U4( C s m a d b s o5i p i S I t V o s 26C s d n i d s w m7b8m u t F F D a C A 2 U 3 e9s0b1(2c o l o w w a b t3t t n o o i m i n o4d o a l t o a m d o5d o t t p o p w i f m6d o d s s a w t f7p o i r t b t p o o t h b8d9(0( D o D C m t p o t N1S P w a a t e t U C1L52]
[DELETED: S(u o a r s p t a m o i b po c n t p t c s f sd( D m t d o t b a od(0( D m ( a r i t o U1S P o H P o t U2S3( s i f u i t d c m4t5s6s7o8( D o d m t a c o9a0w1(2( M m a p o t p o t g3c4m5i6( M d n i t m s o s p7h t e o i f t p8f9p a o c m s d m o0p o s m s t s s o s p1w i i o g o c c i a d1L52]
[DELETED: p(( W t w o m i r t i t UCs o o c i t p o l ea( M m t p p pci b e f s o n o0i b m o c s o b a c o1e a c s a i a p o2r3M d n i t p o c o 4c5t6i t b u f t m o m o t7p c c p o l o 8c9p a o d o a c s i0t1o2p o o a a i t r t o c3a4( N d m a o t f w p5d6i b m o c s o b a c o7e a c s ( O o p a p8s c l a o ( a c m s9d0s1t1L52]
[DELETED: se t t w n d a u i t U CSc l w e d n c c o e oi( O m a s h a a oa l s t m o b c oc i a d h s a o as0o1a2(3L4( P s m a p e t s o t o5p6(7l8( P m a p a p a 9d a v a p a p a o 0c n m a c r n a 1n2a o p l r o o p t3d d p c r w r t o4a5i t s i a e m s a d i6s7(8h9( I p m a s w i t p0c c u o p p f u a w i a1i c i u o l t b u i t1L52]
[DELETED: mt(( U u m a p w l p chh(( C i m a p o t 0c l e o w a o b o a t1r2g3C4( H o c c m ( t s5r w c o p o f a p o t g6c7s w c t p o m b w o8t9(0i t p o a p a a u t N H1F2p3( H o c c d n i c4c i a d p a b t f F a D5A6( E h d m ( a n d (7t a o p ( p ( a8( s ( p ( a o (9m0(1c1L52]
[DELETED: of i t s i s 2 w l rc s a A p o r idcd( C s a m a s ( tc s o w i s s t t c0s1i2o h e o t c n s t i3s s t o g t t s d4a5S I o S I c s a p i s627h8o9a0(1s2w334f5t6i u f t p u s 5 o t F7F8J9p0( A s m a d o h s1c a p r t t ( t1L52]
[DELETED: ea i a c s i S I o s2en s a h b a b t S o H aH S f s a b i a p pdbs0(1a2s3t p t s 2 C o d n i 4p5(6f7(8b9( R m a p w h a c s0r1o2(3a4b r i a m t d o o5e6(7h8f980( F m a c g b a s t e 1d1L52]
[DELETED: oe( E s h t d f i s8( E t m t o i ie f E t i ct(i0l1a n f o a s n f a s t a2d3(4( C r a m a c c o5s t a t s o m r s6t o a d t p o b a a7o8h b C r a d n i c9c i a d p a b t f F a D0A1(2( A p o t l o t m s p i t3p4(576( ( L s m a p o s n7s8i9t r b t i p e o t h b t0r1c s o t p o o m o t f1L52]
[DELETED: i(t t u w a e h m es o a e o t h b t r om(los0( T p o s i m o a f 1p u o p a t c o t p o s i2d3a4( T p o l o t p o s c5w6i c w s a f l r c7s8(9e t o a t a d o i o t0p1(2a3s i a s d o t c o t p o4s w r o m e o t h b t t5e c p t u o c o a c6s7(8a v o w s t a p c b o9r o t p o s i t t p o0s1( T p o s c a c o c1L52]
[DELETED: c t d n h a l r t t u op c b t s d p o m ott p p o l o d i a o tpS 2 S 2 R S C S22 T f a t s o c sr0c o t l o e p o t D E1A o t U S D o J a t l2e3S4(5e s a s o i e a e u6s e w t e o s i e7e8(9(0(1k2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1( A N1L52]
[DELETED: p p 1p((pi( 1 ( i oi( P 1 i0o1( A N2p3i4( A N5p i o i s a s6o7( B N8i9( B N0p i o i s a s1o2( B ( n N3p i o a4g5( 3 N6p i o a g i7s8( N9(0( T N1p1L52]
[DELETED: ( P Np i o i s a s oi( U 3m(((( A 3 4 c0b1(2(3(4(5(6(7(8(9(0(1y2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((((((0(1(2( B ( n 1 e3p4( F s t i e e5s a s o i e a e U s6e l i a s o s n i t7s t i a s t i s r t8f9(0m1(2a3(4a5( R o t a r w a a m6w7(8( A o t f o d t s i9a s o i u s e w t0e1t1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5a q o t f h s t s6i7e8t9o0( B T a o n s i b a n1l t 3 31L52]
[DELETED: d N 5d( 4 T a o n si b a n l t 4m(a n l t 4 ap( 4 T a o n s0i b a n l t 41m2( P T a o n s3i b a n l t 14a5( I T a o n s i b a n6l t 77m ( a ( i a T8i9(0(1(2(3( P P s m a p o t p p4c5o6e7o8(9(0(1e1L52]
[DELETED: e o c s o s s d at i w s c s a paa t o i e d i a d pa b t f F a D A D 6 c otoo t s i n i s c ot s s b i r o t n0d1i2F3(4(5(6i728(9( P T a o n s i b a n0l t 31d2(3i b a n l t N (4p N5c6( P a o p T a o n7s i b a n l t 18p9(0M a 3 i1a1L52]
[DELETED: (((( S d o S A S d oS A i a p o t p p cb a S d w g o n t st a e f a p o s p a e cm d m o p o s p is0w1p2(3q4( t ( o t s i t s i5s6u s e e i t s S7n o t s p c i n8i9o c o t s s b i u t0s1p2m o s t o a t t s c3p4( T M t n5c6s7r e o c s a s s8d a t i w s c s a9p a s a t f D 1 c o t0t a t o i D 6 c o t1t1L52]
[DELETED: tiF( N A c c a 3ni r b a a h a h bc c 2 gc 1 1p 1 o0t1o2( N A c c a 1 H3y4o5c c 2 g6c 1 17p 1 o8t9o0( N A c c a 31n2p r b a a h a h b3c c 2 g4c 1 15p 1 o6t7o8( N A c c 9n0i r b a a h a h b1c c 2 g1L52]
[DELETED: c 1 1p 1 oto( P A c c a 3p s w s a t n a ot i r b a a h a h bc c 2 gc 1 10p 1 o1t2o3( C A c c a 24h5t p r b a a h a h b6c c 2 g7c 1 18p 1 o9t0t1( B A c c a 32s3a h a h b c4c5p 1 16m o t g w o n7f s i o o a o t l r s t a8e9(0s1a h c a h b1L52]
[DELETED: c c 12m o t g w o nf s i o o a o t l r s t ae( T A c c a 3t s w s a tn a o t i r b a a h ca h b c c 10m 2 11p 1 o2t3o4( I c A c c a 15c s w s a t n a o t6i r b a a h c a h7b c c 18p 2 19p 1 o0t1a a m b p a 12p3s4t a 1 p a b o5p6( I c A c c a 17c s w s a t n a o t8i r b a a h c a h9b c c 10p 2 11p 1 o1L52]
[DELETED: ta a m b p a 1pst a 1 p a b op( A n o s c cm o p n s l e i ts0F a D A c o c a c1r2( Z 13y i i i e e s4a5i e e a s i p w t s6c7(8q o a s p a l i s (9t0a s o s n i t s t i1s d f p b s o t2p r w a f m r f f r o 3f t r b s w t a g b4s5o6s f a c o t f t o7t r s w o n t c i f8m9( S o t p r b a h h a0t1p1L52]
[DELETED: aa(a(a(a(0o1(223(4a5( 2 w i a6k7( 2 w i8a9( 2 w i0a1( 2 w i a k2a3(4k5( 1 w i a6k7(8k9(0k1( 21L52]
[DELETED: mN( 2mN( Nw i a k a M o 3m( 20m w i a k a 2 o122( 23w4( 2 [5y6( 27y8( N t9b w i a k a 20N1( 12w i a k a b o b3d4(5i6(7(8(9a0( 6 w i a1k1L52]
[DELETED: ( 2 w i a k a 2 5d(( 2 w i ak((4(0( 3 w i a k a1M2( 3 w i a k3a4(5( n 4 w6i7(8q9i a s o s n i t s t i0s d f 2 w i a1k2w3i4a t a p w a a g o w o n f5s o t i r t a e w a a a6h7( 5 w i a k a 58D9(0D1(1L52]
[DELETED: H( 4 w i a k a 4H(5(D( 5 w i a k a 5M0(1D2(3( A s c a q o t f4m5(6(7(8(9(0(1( B o b o2b3(4a5b t i s d b a m f 26a7n o t r s w o n t c i8f9( S i t r s t a e w a0a a h h o h s1w o n f s i t r s b o o m1L52]
[DELETED: o( S a t 3 w a a as( S a t 2 n a w a ods( U s e o u l i asa0t1i w t e o s s i a s o2i3( A 74y a i i s i a s o5i6(7(8(9h 4 4 A S0O1( U s e o u l i a2s3a4c n s i i s i a s o5i6(7(8( A a 2 o 49d0( C 2 a1a1L52]
[DELETED: (i S o n 2 a( 2 aN m me( ( a (p( N Na0(1( 4 ( n 4 42m3( N - p4i i i s i a s o5i6(7(8h9S0( A o t f s e t n d1l i o s w p d o i b2e3c s o b c o e a c4s5( O a o a a s c d o6p o o o o e a b7t b d n n8n9(0(1(1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7c8t9s0(1(2o c l a a s c d o p3t4s5a s o o i e t t s s n6i d c l o e w d n c7c8(9e l s o p f w c t p0a1(1L52]
[DELETED: oasc(((((0(1(2(3(4(5( M 46b7( M 28d9(0(1(2(3( P e4c5( P 16c7(8(9(0(1(1L52]
[DELETED: (((( L w i a k a la((((0(1a q o t f s h a p f a2a3( A i s o i a s o i4o5(6(7(8(9(0a q o t f s h a p f a1a w a d e o t c n s2i t s i a s o i w t3e4t5(6(7(8(9(0(1( N A n f n (1L52]
[DELETED: d 6d(f( U s e o u l i asa( I p t a a mP0t P P b m k a m b1k2(3(4(5(6(7S8(9a q o t f s h a p f a0a w a s e o t c n s1i2a3a s o i i p w t s c4d5(6(7(8(9(0a q o t f s h a p f a1a1L52]
[DELETED: ( A s w c a q o a d obts(((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5( A c m o p c a6s7a8( A s d f c a9s p o a s o a o t d a0a1a1L52]
[DELETED: ( A d p c g ai i s i a s o i f w aaC(n f k (c( T a z o a s t T o on0a1i b a n l t 22c3n l t 44t5( U s e o u l i a6s7( A m c m o p c8l9c0a1( N m t o a e g o c p o2h3w4( N m t o a e g o c p o5h6w o o m a n i i r7t8(9o h m o n m t n m p d0u w o o m a n i i r1t1L52]
[DELETED: (hw o o m a n i i rt(m o p o h g o n m t tm p d u w o o m a ni( N m t f m o m p o h0m1i2(3o4(5(6D E A o t U S D o7J8w s i a m c m o p9c0i a s o i w t e o s s o1i2(3(4(5( 1 (6e7( 1 (8e9(0(1(1L52]
[DELETED: ((( B (h(((e(0( D (1a2( D (3e4( D ( '5h6(7( D (8a9(0( F (1d2( F ( (3a4( F (5f6(7(8( 4 (9o0( M (1o1L52]
[DELETED: ( M (o( M (d(e( M (b( M (0o1(2(3(4( 1 (5h6( M (7d8( M (9t0( M (1e2( M (3e4( 1 (5h ( '6m7(8(9(0(1(1L52]
[DELETED: ( 1 (d((( N ( 1e(( N (o0( N (1o2( O (3a4( O (5e6( O (7h8( P (9c0( S (1a2( S (3o4( T (5o6(7( T ( 18h9(0(1(1L52]
[DELETED: ((((((( 2 a 3 a a ab(0( 4 a b1d2(3(4(5(6(7(8(9(0(1(2l3g4(5(6g7A S o n f d a (8t9(0S1(1L52]
[DELETED: aas(((( C b n i l (h a c b o m ( aw0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((a q o t f s i i s iw o p o g a s o s iwp0( U s e o u l i a1s2a3c4p5o s s i a s o i i p w t6s7(8(9( P i o c a c0t1(2(3(4(5(6(7(8(9(0( U s e o u l i a1s1L52]
[DELETED: aca(( N m t o m o d a n l tt( 2 is o a g i a s o t i ti0( U s e o u l i a1s2a3s4(5(6(7a8i9i0( U s e o u l i a1s2a q o t f s i i s o3i4( T f d p c e i s5o i a s o s o i a e f6s ( o S I i t ( a s b 7c8t a c n a f a e t a t d9p0c1o1L52]
[DELETED: p r o o a m t t a sg o e b d a t p n cs p r o o a m t n g oeacpm c w t p O T F o FM0u1(2i3h4(5(6S7( A c m o p c a o t8f9f a b o a w s i o o m0n a m i i s p t1c u t c m o p v m2q3(4m5(6h7( N m t o h m o e p o8h9( N m t t a f m o d0a1u1L52]
[DELETED: (m( N m t f m o d a n lt( U s e o e o u l iac a q o t f s h a ses0( U s e o e o u l i1a2c a q o t f s h a d3e4s5( E (6a7(8(9(0( B (1b2s3(4(5S 3  O s 2 a 2 R S6C1L52]


================================================================================

Raw Text:
LB431 LB431
2025 2025
LEGISLATURE OF NEBRASKA
ONE HUNDRED NINTH LEGISLATURE
FIRST SESSION
LEGISLATIVE BILL 431
Introduced by Lippincott, 34; Murman, 38.
Read first time January 17, 2025
Committee: Judiciary
1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to
2 amend sections 28-401 and 28-405, Revised Statutes Cumulative
3 Supplement, 2024; to prohibit kratom as a controlled substance; to
4 define a term; and to repeal the original sections.
5 Be it enacted by the people of the State of Nebraska,
-1-

LB431 LB431
2025 2025
1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement,
2 2024, is amended to read:
3 28-401 As used in the Uniform Controlled Substances Act, unless the
4 context otherwise requires:
5 (1) Administer means to directly apply a controlled substance by
6 injection, inhalation, ingestion, or any other means to the body of a
7 patient or research subject;
8 (2) Agent means an authorized person who acts on behalf of or at the
9 direction of another person but does not include a common or contract
10 carrier, public warehouse keeper, or employee of a carrier or warehouse
11 keeper;
12 (3) Administration means the Drug Enforcement Administration of the
13 United States Department of Justice;
14 (4) Controlled substance means a drug, biological, substance, or
15 immediate precursor in Schedules I through V of section 28-405.
16 Controlled substance does not include distilled spirits, wine, malt
17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance
18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et
19 seq., as such act existed on January 1, 2014, and the law of this state,
20 be lawfully sold over the counter without a prescription;
21 (5) Counterfeit substance means a controlled substance which, or the
22 container or labeling of which, without authorization, bears the
23 trademark, trade name, or other identifying mark, imprint, number, or
24 device, or any likeness thereof, of a manufacturer, distributor, or
25 dispenser other than the person or persons who in fact manufactured,
26 distributed, or dispensed such substance and which thereby falsely
27 purports or is represented to be the product of, or to have been
28 distributed by, such other manufacturer, distributor, or dispenser;
29 (6) Department means the Department of Health and Human Services;
30 (7) Division of Drug Control means the personnel of the Nebraska
31 State Patrol who are assigned to enforce the Uniform Controlled
-2-

LB431 LB431
2025 2025
1 Substances Act;
2 (8) Dispense means to deliver a controlled substance to an ultimate
3 user or a research subject pursuant to a medical order issued by a
4 practitioner authorized to prescribe, including the packaging, labeling,
5 or compounding necessary to prepare the controlled substance for such
6 delivery;
7 (9) Distribute means to deliver other than by administering or
8 dispensing a controlled substance;
9 (10) Prescribe means to issue a medical order;
10 (11) Drug means (a) articles recognized in the official United
11 States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United
12 States, official National Formulary, or any supplement to any of them,
13 (b) substances intended for use in the diagnosis, cure, mitigation,
14 treatment, or prevention of disease in human beings or animals, and (c)
15 substances intended for use as a component of any article specified in
16 subdivision (a) or (b) of this subdivision, but does not include devices
17 or their components, parts, or accessories;
18 (12) Deliver or delivery means the actual, constructive, or
19 attempted transfer from one person to another of a controlled substance,
20 whether or not there is an agency relationship;
21 (13) Hemp has the same meaning as in section 2-503;
22 (14)(a) Marijuana means all parts of the plant of the genus
23 cannabis, whether growing or not, the seeds thereof, and every compound,
24 manufacture, salt, derivative, mixture, or preparation of such plant or
25 its seeds.
26 (b) Marijuana does not include the mature stalks of such plant,
27 hashish, tetrahydrocannabinols extracted or isolated from the plant,
28 fiber produced from such stalks, oil or cake made from the seeds of such
29 plant, any other compound, manufacture, salt, derivative, mixture, or
30 preparation of such mature stalks, the sterilized seed of such plant
31 which is incapable of germination, or cannabidiol contained in a drug
-3-

LB431 LB431
2025 2025
1 product approved by the federal Food and Drug Administration.
2 (c) Marijuana does not include hemp.
3 (d) When the weight of marijuana is referred to in the Uniform
4 Controlled Substances Act, it means its weight at or about the time it is
5 seized or otherwise comes into the possession of law enforcement
6 authorities, whether cured or uncured at that time;
7 (15) Manufacture means the production, preparation, propagation,
8 conversion, or processing of a controlled substance, either directly or
9 indirectly, by extraction from substances of natural origin,
10 independently by means of chemical synthesis, or by a combination of
11 extraction and chemical synthesis, and includes any packaging or
12 repackaging of the substance or labeling or relabeling of its container.
13 Manufacture does not include the preparation or compounding of a
14 controlled substance by an individual for his or her own use, except for
15 the preparation or compounding of components or ingredients used for or
16 intended to be used for the manufacture of methamphetamine, or the
17 preparation, compounding, conversion, packaging, or labeling of a
18 controlled substance: (a) By a practitioner as an incident to his or her
19 prescribing, administering, or dispensing of a controlled substance in
20 the course of his or her professional practice; or (b) by a practitioner,
21 or by his or her authorized agent under his or her supervision, for the
22 purpose of, or as an incident to, research, teaching, or chemical
23 analysis and not for sale;
24 (16) Narcotic drug means any of the following, whether produced
25 directly or indirectly by extraction from substances of vegetable origin,
26 independently by means of chemical synthesis, or by a combination of
27 extraction and chemical synthesis: (a) Opium, opium poppy and poppy
28 straw, coca leaves, and opiates; (b) a compound, manufacture, salt,
29 derivative, or preparation of opium, coca leaves, or opiates; or (c) a
30 substance and any compound, manufacture, salt, derivative, or preparation
31 thereof which is chemically equivalent to or identical with any of the
-4-

LB431 LB431
2025 2025
1 substances referred to in subdivisions (a) and (b) of this subdivision,
2 except that the words narcotic drug as used in the Uniform Controlled
3 Substances Act does not include decocainized coca leaves or extracts of
4 coca leaves, which extracts do not contain cocaine or ecgonine, or
5 isoquinoline alkaloids of opium;
6 (17) Opiate means any substance having an addiction-forming or
7 addiction-sustaining liability similar to morphine or being capable of
8 conversion into a drug having such addiction-forming or addiction-
9 sustaining liability. Opiate does not include the dextrorotatory isomer
10 of 3-methoxy-n methylmorphinan and its salts. Opiate includes its racemic
11 and levorotatory forms;
12 (18) Opium poppy means the plant of the species Papaver somniferum
13 L., except the seeds thereof;
14 (19) Poppy straw means all parts, except the seeds, of the opium
15 poppy after mowing;
16 (20) Person means any corporation, association, partnership, limited
17 liability company, or one or more persons;
18 (21) Practitioner means a physician, a physician assistant, a
19 dentist, a veterinarian, a pharmacist, a podiatrist, an optometrist, a
20 certified nurse midwife, a certified registered nurse anesthetist, a
21 nurse practitioner, a scientific investigator, a pharmacy, a hospital, or
22 any other person licensed, registered, or otherwise permitted to
23 distribute, dispense, prescribe, conduct research with respect to, or
24 administer a controlled substance in the course of practice or research
25 in this state, including an emergency medical service as defined in
26 section 38-1207;
27 (22) Production includes the manufacture, planting, cultivation, or
28 harvesting of a controlled substance;
29 (23) Immediate precursor means a substance which is the principal
30 compound commonly used or produced primarily for use and which is an
31 immediate chemical intermediary used or likely to be used in the
-5-

LB431 LB431
2025 2025
1 manufacture of a controlled substance, the control of which is necessary
2 to prevent, curtail, or limit such manufacture;
3 (24) State means the State of Nebraska;
4 (25) Ultimate user means a person who lawfully possesses a
5 controlled substance for his or her own use, for the use of a member of
6 his or her household, or for administration to an animal owned by him or
7 her or by a member of his or her household;
8 (26) Hospital has the same meaning as in section 71-419;
9 (27) Cooperating individual means any person, other than a
10 commissioned law enforcement officer, who acts on behalf of, at the
11 request of, or as agent for a law enforcement agency for the purpose of
12 gathering or obtaining evidence of offenses punishable under the Uniform
13 Controlled Substances Act;
14 (28)(a) Hashish or concentrated cannabis means (i) the separated
15 resin, whether crude or purified, obtained from a plant of the genus
16 cannabis or (ii) any material, preparation, mixture, compound, or other
17 substance which contains ten percent or more by weight of
18 tetrahydrocannabinols.
19 (b) When resins extracted from hemp as defined in section 2-503 are
20 in the possession of a person as authorized under the Nebraska Hemp
21 Farming Act, they are not considered hashish or concentrated cannabis for
22 purposes of the Uniform Controlled Substances Act.
23 (c) Hashish or concentrated cannabis does not include cannabidiol
24 contained in a drug product approved by the federal Food and Drug
25 Administration;
26 (29) Exceptionally hazardous drug means (a) a narcotic drug, (b)
27 thiophene analog of phencyclidine, (c) phencyclidine, (d) amobarbital,
28 (e) secobarbital, (f) pentobarbital, (g) amphetamine, or (h)
29 methamphetamine;
30 (30) Imitation controlled substance means a substance which is not a
31 controlled substance or controlled substance analogue but which, by way
-6-

LB431 LB431
2025 2025
1 of express or implied representations and consideration of other relevant
2 factors including those specified in section 28-445, would lead a
3 reasonable person to believe the substance is a controlled substance or
4 controlled substance analogue. A placebo or registered investigational
5 drug manufactured, distributed, possessed, or delivered in the ordinary
6 course of practice or research by a health care professional shall not be
7 deemed to be an imitation controlled substance;
8 (31)(a) Controlled substance analogue means a substance (i) the
9 chemical structure of which is substantially similar to the chemical
10 structure of a Schedule I or Schedule II controlled substance as provided
11 in section 28-405 or (ii) which has a stimulant, depressant, analgesic,
12 or hallucinogenic effect on the central nervous system that is
13 substantially similar to or greater than the stimulant, depressant,
14 analgesic, or hallucinogenic effect on the central nervous system of a
15 Schedule I or Schedule II controlled substance as provided in section
16 28-405. A controlled substance analogue shall, to the extent intended for
17 human consumption, be treated as a controlled substance under Schedule I
18 of section 28-405 for purposes of the Uniform Controlled Substances Act;
19 and
20 (b) Controlled substance analogue does not include (i) a controlled
21 substance, (ii) any substance generally recognized as safe and effective
22 within the meaning of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
23 301 et seq., as such act existed on January 1, 2014, (iii) any substance
24 for which there is an approved new drug application, or (iv) with respect
25 to a particular person, any substance if an exemption is in effect for
26 investigational use for that person, under section 505 of the Federal
27 Food, Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
28 January 1, 2014, to the extent conduct with respect to such substance is
29 pursuant to such exemption;
30 (32) Anabolic steroid means any drug or hormonal substance,
31 chemically and pharmacologically related to testosterone (other than
-7-

LB431 LB431
2025 2025
1 estrogens, progestins, and corticosteroids), that promotes muscle growth
2 and includes any controlled substance in Schedule III(d) of section
3 28-405. Anabolic steroid does not include any anabolic steroid which is
4 expressly intended for administration through implants to cattle or other
5 nonhuman species and has been approved by the Secretary of Health and
6 Human Services for such administration, but if any person prescribes,
7 dispenses, or distributes such a steroid for human use, such person shall
8 be considered to have prescribed, dispensed, or distributed an anabolic
9 steroid within the meaning of this subdivision;
10 (33) Chart order means an order for a controlled substance issued by
11 a practitioner for a patient who is in the hospital where the chart is
12 stored or for a patient receiving detoxification treatment or maintenance
13 treatment pursuant to section 28-412. Chart order does not include a
14 prescription;
15 (34) Medical order means a prescription, a chart order, or an order
16 for pharmaceutical care issued by a practitioner;
17 (35) Prescription means an order for a controlled substance issued
18 by a practitioner. Prescription does not include a chart order;
19 (36) Registrant means any person who has a controlled substances
20 registration issued by the state or the Drug Enforcement Administration
21 of the United States Department of Justice;
22 (37) Reverse distributor means a person whose primary function is to
23 act as an agent for a pharmacy, wholesaler, manufacturer, or other entity
24 by receiving, inventorying, and managing the disposition of outdated,
25 expired, or otherwise nonsaleable controlled substances;
26 (38) Signature means the name, word, or mark of a person written in
27 his or her own hand with the intent to authenticate a writing or other
28 form of communication or a digital signature which complies with section
29 86-611 or an electronic signature;
30 (39) Facsimile means a copy generated by a system that encodes a
31 document or photograph into electrical signals, transmits those signals
-8-

LB431 LB431
2025 2025
1 over telecommunications lines, and reconstructs the signals to create an
2 exact duplicate of the original document at the receiving end;
3 (40) Electronic signature has the definition found in section
4 86-621;
5 (41) Electronic transmission means transmission of information in
6 electronic form. Electronic transmission includes computer-to-computer
7 transmission or computer-to-facsimile transmission;
8 (42) Long-term care facility means an intermediate care facility, an
9 intermediate care facility for persons with developmental disabilities, a
10 long-term care hospital, a mental health substance use treatment center,
11 a nursing facility, or a skilled nursing facility, as such terms are
12 defined in the Health Care Facility Licensure Act;
13 (43) Compounding has the same meaning as in section 38-2811;
14 (44) Cannabinoid receptor agonist means any chemical compound or
15 substance that, according to scientific or medical research, study,
16 testing, or analysis, demonstrates the presence of binding activity at
17 one or more of the CB1 or CB2 cell membrane receptors located within the
18 human body. Cannabinoid receptor agonist does not include cannabidiol
19 contained in a drug product approved by the federal Food and Drug
20 Administration; and
21 (45) Kratom means any product or ingredient containing:
22 (a) Any part of the leaf of the mitragyna speciosa plant if the
23 plant contains the alkaloid mitragynine or 7-hydroxymitragynine; or
24 (b) A synthetic material that contains the alkaloid mitragynine or
25 7-hydroxymitragynine; and
26 (46) (45) Lookalike substance means a product or substance, not
27 specifically designated as a controlled substance in section 28-405, that
28 is either portrayed in such a manner by a person to lead another person
29 to reasonably believe that it produces effects on the human body that
30 replicate, mimic, or are intended to simulate the effects produced by a
31 controlled substance or that possesses one or more of the following
-9-

LB431 LB431
2025 2025
1 indicia or characteristics:
2 (a) The packaging or labeling of the product or substance suggests
3 that the user will achieve euphoria, hallucination, mood enhancement,
4 stimulation, or another effect on the human body that replicates or
5 mimics those produced by a controlled substance;
6 (b) The name or packaging of the product or substance uses images or
7 labels suggesting that it is a controlled substance or produces effects
8 on the human body that replicate or mimic those produced by a controlled
9 substance;
10 (c) The product or substance is marketed or advertised for a
11 particular use or purpose and the cost of the product or substance is
12 disproportionately higher than other products or substances marketed or
13 advertised for the same or similar use or purpose;
14 (d) The packaging or label on the product or substance contains
15 words or markings that state or suggest that the product or substance is
16 in compliance with state and federal laws regulating controlled
17 substances;
18 (e) The owner or person in control of the product or substance uses
19 evasive tactics or actions to avoid detection or inspection of the
20 product or substance by law enforcement authorities;
21 (f) The owner or person in control of the product or substance makes
22 a verbal or written statement suggesting or implying that the product or
23 substance is a synthetic drug or that consumption of the product or
24 substance will replicate or mimic effects on the human body to those
25 effects commonly produced through use or consumption of a controlled
26 substance;
27 (g) The owner or person in control of the product or substance makes
28 a verbal or written statement to a prospective customer, buyer, or
29 recipient of the product or substance implying that the product or
30 substance may be resold for profit; or
31 (h) The product or substance contains a chemical or chemical
-10-

LB431 LB431
2025 2025
1 compound that does not have a legitimate relationship to the use or
2 purpose claimed by the seller, distributor, packer, or manufacturer of
3 the product or substance or indicated by the product name, appearing on
4 the product's packaging or label or depicted in advertisement of the
5 product or substance.
6 Sec. 2. Section 28-405, Revised Statutes Cumulative Supplement,
7 2024, is amended to read:
8 28-405 The following are the schedules of controlled substances
9 referred to in the Uniform Controlled Substances Act, unless specifically
10 contained on the list of exempted products of the Drug Enforcement
11 Administration of the United States Department of Justice as the list
12 existed on January 31, 2022:
13 Schedule I
14 (a) Any of the following opiates, including their isomers, esters,
15 ethers, salts, and salts of isomers, esters, and ethers, unless
16 specifically excepted, whenever the existence of such isomers, esters,
17 ethers, and salts is possible within the specific chemical designation:
18 (1) Acetylmethadol;
19 (2) Allylprodine;
20 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
21 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
22 (4) Alphameprodine;
23 (5) Alphamethadol;
24 (6) Benzethidine;
25 (7) Betacetylmethadol;
26 (8) Betameprodine;
27 (9) Betamethadol;
28 (10) Betaprodine;
29 (11) Clonitazene;
30 (12) Dextromoramide;
31 (13) Difenoxin;
-11-

LB431 LB431
2025 2025
1 (14) Diampromide;
2 (15) Diethylthiambutene;
3 (16) Dimenoxadol;
4 (17) Dimepheptanol;
5 (18) Dimethylthiambutene;
6 (19) Dioxaphetyl butyrate;
7 (20) Dipipanone;
8 (21) Ethylmethylthiambutene;
9 (22) Etonitazene;
10 (23) Etoxeridine;
11 (24) Furethidine;
12 (25) Hydroxypethidine;
13 (26) Ketobemidone;
14 (27) Levomoramide;
15 (28) Levophenacylmorphan;
16 (29) Morpheridine;
17 (30) Noracymethadol;
18 (31) Norlevorphanol;
19 (32) Normethadone;
20 (33) Norpipanone;
21 (34) Phenadoxone;
22 (35) Phenampromide;
23 (36) Phenomorphan;
24 (37) Phenoperidine;
25 (38) Piritramide;
26 (39) Proheptazine;
27 (40) Properidine;
28 (41) Propiram;
29 (42) Racemoramide;
30 (43) Trimeperidine;
31 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
-12-

LB431 LB431
2025 2025
1 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
2 piperidine;
3 (45) Tilidine;
4 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
5 phenylpropanamide, its optical and geometric isomers, salts, and salts of
6 isomers;
7 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
8 isomers, salts, and salts of isomers;
9 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
10 optical isomers, salts, and salts of isomers;
11 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
12 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
13 isomers;
14 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
16 of isomers;
17 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
18 its optical isomers, salts, and salts of isomers;
19 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
20 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
21 of isomers;
22 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
23 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
24 geometric isomers, salts, and salts of isomers;
25 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
26 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
27 salts, and salts of isomers;
28 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
29 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
30 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
31 propanamide, its optical isomers, salts, and salts of isomers;
-13-

LB431 LB431
2025 2025
1 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
2 piperidinyl)propanamide, its optical isomers, salts, and salts of
3 isomers;
4 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
5 methylbenzamide;
6 (59) 4-Fluoroisobutyryl Fentanyl;
7 (60) Acetyl Fentanyl;
8 (61) Acyrloylfentanyl;
9 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
10 benzamide;
11 (63) Butyryl fentanyl;
12 (64) Cyclopentyl fentanyl;
13 (65) Cyclopropyl fentanyl;
14 (66) Furanyl fentanyl;
15 (67) Isobutyryl fentanyl;
16 (68) Isotonitazene;
17 (69) Methoxyacetyl fentanyl;
18 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
19 (71) Tetrahydrofuranyl fentanyl;
20 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
21 yl) propionamide;
22 (73) Ocfentanil;
23 (74) Ortho-Fluorofentanyl;
24 (75) Para-chloroisobutyryl fentanyl;
25 (76) Para-Fluorobutyryl Fentanyl;
26 (77) Valeryl fentanyl;
27 (78) Phenyl Fentanyl;
28 (79) Para-Methylfentanyl;
29 (80) Thiofuranyl Fentanyl;
30 (81) Beta-methyl Fentanyl;
31 (82) Beta'-Phenyl Fentanyl;
-14-

LB431 LB431
2025 2025
1 (83) Crotonyl Fentanyl;
2 (84) 2'-Fluoro Ortho-Fluorofentanyl;
3 (85) 4'-Methyl Acetyl Fentanyl;
4 (86) Ortho-Fluorobutyryl Fentanyl;
5 (87) Ortho-Methyl Acetylfentanyl;
6 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
7 (89) Ortho-Fluoroacryl Fentanyl;
8 (90) Fentanyl Carbamate;
9 (91) Ortho-Fluoroisobutyryl Fentanyl;
10 (92) Para-Fluoro Furanyl Fentanyl;
11 (93) Para-Methoxybutyryl Fentanyl;
12 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
13 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
14 (95) Fentanyl-related substances, their isomers, esters, ethers,
15 salts and salts of isomers, esters, and ethers. Unless specifically
16 excepted, listed in another schedule, or specifically named in this
17 schedule, this includes any substance that is structurally related to
18 fentanyl by one or more of the following modifications:
19 (A) Replacement of the phenyl portion of the phenethyl group by any
20 monocycle, whether or not further substituted in or on the monocycle;
21 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
22 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
23 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
24 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
25 (D) Replacement of the aniline ring with any aromatic monocycle
26 whether or not further substituted in or on the aromatic monocycle; or
27 (E) Replacement of the N-propionyl group by another acyl group.
28 (b) Any of the following opium derivatives, their salts, isomers,
29 and salts of isomers, unless specifically excepted, whenever the
30 existence of such salts, isomers, and salts of isomers is possible within
31 the specific chemical designation:
-15-

LB431 LB431
2025 2025
1 (1) Acetorphine;
2 (2) Acetyldihydrocodeine;
3 (3) Benzylmorphine;
4 (4) Codeine methylbromide;
5 (5) Codeine-N-Oxide;
6 (6) Cyprenorphine;
7 (7) Desomorphine;
8 (8) Dihydromorphine;
9 (9) Drotebanol;
10 (10) Etorphine, except hydrochloride salt;
11 (11) Heroin;
12 (12) Hydromorphinol;
13 (13) Methyldesorphine;
14 (14) Methyldihydromorphine;
15 (15) Morphine methylbromide;
16 (16) Morphine methylsulfonate;
17 (17) Morphine-N-Oxide;
18 (18) Myrophine;
19 (19) Nicocodeine;
20 (20) Nicomorphine;
21 (21) Normorphine;
22 (22) Pholcodine; and
23 (23) Thebacon.
24 (c) Any material, compound, mixture, or preparation which contains
25 any quantity of the following hallucinogenic substances, their salts,
26 isomers, and salts of isomers, unless specifically excepted, whenever the
27 existence of such salts, isomers, and salts of isomers is possible within
28 the specific chemical designation, and, for purposes of this subdivision
29 only, isomer shall include the optical, position, and geometric isomers:
30 (1) Bufotenine. Trade and other names shall include, but are not
31 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
-16-

LB431 LB431
2025 2025
1 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
2 dimethyltryptamine; and mappine;
3 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
4 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
5 methylphenethylamine; and 4-bromo-2,5-DMA;
6 (3) 4-methoxyamphetamine. Trade and other names shall include, but
7 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
8 paramethoxyamphetamine, PMA;
9 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
10 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
11 methylphenethylamine; DOM; and STP;
12 (5) Para-methoxymethamphetamine. Trade and other names shall
13 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
14 amine, PMMA, and 4-MMA;
15 (6) Ibogaine. Trade and other names shall include, but are not
16 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
17 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
18 iboga;
19 (7) Lysergic acid diethylamide;
20 (8) Marijuana;
21 (9) Mescaline;
22 (10) Methoxetamine (MXE);
23 (11) Peyote. Peyote shall mean all parts of the plant presently
24 classified botanically as Lophophora williamsii Lemaire, whether growing
25 or not, the seeds thereof, any extract from any part of such plant, and
26 every compound, manufacture, salts, derivative, mixture, or preparation
27 of such plant or its seeds or extracts;
28 (12) Psilocybin;
29 (13) Psilocyn;
30 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
31 equivalents of the substances contained in the plant or in the resinous
-17-

LB431 LB431
2025 2025
1 extractives of cannabis, sp. or synthetic substances, derivatives, and
2 their isomers with similar chemical structure and pharmacological
3 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
4 and their optical isomers, excluding dronabinol in a drug product
5 approved by the federal Food and Drug Administration; Delta 6 cis or
6 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
7 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
8 of these substances is not internationally standardized, compounds of
9 these structures shall be included regardless of the numerical
10 designation of atomic positions covered. Tetrahydrocannabinols does not
11 include cannabidiol contained in a drug product approved by the federal
12 Food and Drug Administration;
13 (15) N-ethyl-3-piperidyl benzilate;
14 (16) N-methyl-3-piperidyl benzilate;
15 (17) Thiophene analog of phencyclidine. Trade and other names shall
16 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
17 2-thienyl analog of phencyclidine; TPCP; and TCP;
18 (18) Hashish or concentrated cannabis;
19 (19) Parahexyl. Trade and other names shall include, but are not
20 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
21 dibenzo(b,d)pyran; and Synhexyl;
22 (20) Ethylamine analog of phencyclidine. Trade and other names shall
23 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
24 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
25 cyclohexamine; and PCE;
26 (21) Pyrrolidine analog of phencyclidine. Trade and other names
27 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
28 pyrrolidine; PCPy; and PHP;
29 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
30 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
31 alpha-ET; and AET;
-18-

LB431 LB431
2025 2025
1 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
2 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
3 (25) Alpha-methyltryptamine, which is also known as AMT;
4 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
5 Salvinorin A includes all parts of the plant presently classified
6 botanically as Salvia divinorum, whether growing or not, the seeds
7 thereof, any extract from any part of such plant, and every compound,
8 manufacture, derivative, mixture, or preparation of such plant, its
9 seeds, or its extracts, including salts, isomers, and salts of isomers
10 whenever the existence of such salts, isomers, and salts of isomers is
11 possible within the specific chemical designation;
12 (27) Any material, compound, mixture, or preparation containing any
13 quantity of synthetically produced cannabinoids as listed in subdivisions
14 (A) through (L) of this subdivision, including their salts, isomers,
15 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
16 unless specifically excepted elsewhere in this section. Since
17 nomenclature of these synthetically produced cannabinoids is not
18 internationally standardized and may continually evolve, these structures
19 or compounds of these structures shall be included under this
20 subdivision, regardless of their specific numerical designation of atomic
21 positions covered, so long as it can be determined through a recognized
22 method of scientific testing or analysis that the substance contains
23 properties that fit within one or more of the following categories:
24 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
25 contained in a plant of the genus cannabis (cannabis plant), as well as
26 synthetic equivalents of the substances contained in the plant, or in the
27 resinous extractives of cannabis, sp. and/or synthetic substances,
28 derivatives, and their isomers with similar chemical structure and
29 pharmacological activity such as the following: Delta 1 cis or trans
30 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
31 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
-19-

LB431 LB431
2025 2025
1 tetrahydrocannabinol, and its optical isomers. This subdivision does not
2 include cannabidiol contained in a drug product approved by the federal
3 Food and Drug Administration;
4 (B) Naphthoylindoles: Any compound containing a 3-(1-
5 naphthoyl)indole structure with substitution at the nitrogen atom of the
6 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
7 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
8 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
9 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
10 tetrahydropyranylmethyl group, whether or not further substituted in or
11 on any of the listed ring systems to any extent;
12 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
13 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
14 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
15 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
16 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
17 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
18 tetrahydropyranylmethyl group, whether or not further substituted in or
19 on any of the listed ring systems to any extent;
20 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
21 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
22 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
23 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
24 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
25 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
26 tetrahydropyranylmethyl group, whether or not further substituted in or
27 on any of the listed ring systems to any extent;
28 (E) Naphthylideneindenes: Any compound containing a
29 naphthylideneindene structure with substitution at the 3-position of the
30 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
31 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
-20-

LB431 LB431
2025 2025
1 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
2 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
3 tetrahydropyranylmethyl group, whether or not further substituted in or
4 on any of the listed ring systems to any extent;
5 (F) Phenylacetylindoles: Any compound containing a 3-
6 phenylacetylindole structure with substitution at the nitrogen atom of
7 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
8 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
9 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
10 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
11 tetrahydropyranylmethyl group, whether or not further substituted in or
12 on any of the listed ring systems to any extent;
13 (G) Cyclohexylphenols: Any compound containing a 2-(3-
14 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
15 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
16 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
17 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
18 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
19 tetrahydropyranylmethyl group, whether or not substituted in or on any of
20 the listed ring systems to any extent;
21 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
22 structure with substitution at the nitrogen atom of the indole ring by an
23 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
24 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
25 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
26 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
27 further substituted in or on any of the listed ring systems to any
28 extent;
29 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
30 structure with substitution at the nitrogen atom of the indole ring by an
31 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
-21-

LB431 LB431
2025 2025
1 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
2 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
3 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
4 further substituted in or on any of the listed ring systems to any
5 extent;
6 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
7 tetramethylcyclopropanoylindole structure with substitution at the
8 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
9 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
10 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
12 tetrahydropyranylmethyl group, whether or not further substituted in or
13 on any of the listed ring systems to any extent;
14 (K) Indole carboxamides: Any compound containing a 1-indole-3-
15 carboxamide structure with substitution at the nitrogen atom of the
16 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
17 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
18 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
19 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
20 tetrahydropyranylmethyl group, substitution at the carboxamide group by
21 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
22 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
23 substituted in or on any of the listed ring systems to any extent or to
24 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
25 propionaldehyde groups to any extent;
26 (L) Indole carboxylates: Any compound containing a 1-indole-3-
27 carboxylate structure with substitution at the nitrogen atom of the
28 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
29 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
30 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
31 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
-22-

LB431 LB431
2025 2025
1 tetrahydropyranylmethyl group, substitution at the carboxylate group by
2 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
3 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
4 substituted in or on any of the listed ring systems to any extent or to
5 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
6 propionaldehyde groups to any extent; and
7 (M) Any nonnaturally occurring substance, chemical compound,
8 mixture, or preparation, not specifically listed elsewhere in these
9 schedules and which is not approved for human consumption by the federal
10 Food and Drug Administration, containing or constituting a cannabinoid
11 receptor agonist as defined in section 28-401;
12 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
13 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
14 and salts of isomers, esters, and ethers, whenever the existence of such
15 isomers, esters, ethers, and salts is possible within the specific
16 chemical designation;
17 (29) Any material, compound, mixture, or preparation containing any
18 quantity of a substituted phenethylamine as listed in subdivisions (A)
19 through (C) of this subdivision, unless specifically excepted, listed in
20 another schedule, or specifically named in this schedule, that is
21 structurally derived from phenylethan-2-amine by substitution on the
22 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
23 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
24 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
25 or tetrahydropyran ring system; or by substitution with two fused ring
26 systems from any combination of the furan, tetrahydrofuran, or
27 tetrahydropyran ring systems, whether or not the compound is further
28 modified in any of the following ways:
29 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
30 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
31 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
-23-

LB431 LB431
2025 2025
1 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
2 and including, but not limited to:
3 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
4 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
5 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
6 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
7 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
8 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
9 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
10 or 2,5-Dimethoxyphenethylamine;
11 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
12 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
13 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
14 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
15 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
16 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
17 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
18 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
19 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
20 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
21 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
22 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
23 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
24 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
25 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
26 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
27 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
28 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
29 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
30 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
31 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
-24-

LB431 LB431
2025 2025
1 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
2 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
3 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
4 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
5 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
6 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
7 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
8 methoxybenzyl)phenethylamine;
9 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
10 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
11 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
12 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
13 which is also known as 2CB-5-hemiFLY;
14 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
15 yl)ethanamine, which is also known as 2C-B-FLY;
16 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
17 yl)ethanamine, which is also known as 2C-B-butterFLY;
18 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
19 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
20 NBOMe;
21 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
22 which is also known as bromo-benzodifuranylisopropylamine or bromo-
23 dragonFLY;
24 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
25 is also known as 2C-INBOH or 25I-NBOH;
26 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
27 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
28 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
29 as 5-APDB;
30 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
31 known as 6-APDB;
-25-

LB431 LB431
2025 2025
1 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
2 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
3 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
4 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
5 known as 2C-T-7;
6 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
7 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
8 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
9 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
10 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
11 MDMA;
12 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
13 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
14 (xxxvii) 3,4,5-trimethoxy amphetamine; and
15 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
16 is also known as N-hydroxyMDA;
17 (30) Any material, compound, mixture, or preparation containing any
18 quantity of a substituted tryptamine unless specifically excepted, listed
19 in another schedule, or specifically named in this schedule, that is
20 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
21 known as tryptamine, by mono- or di-substitution of the amine nitrogen
22 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
23 in a cyclic structure whether or not the compound is further substituted
24 at the alpha position with an alkyl group or whether or not further
25 substituted on the indole ring to any extent with any alkyl, alkoxy,
26 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
27 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
28 DALT;
29 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
30 DMT or OAcetylpsilocin;
31 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
-26-

LB431 LB431
2025 2025
1 HO-MET;
2 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
3 HO-DIPT;
4 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
5 5-MeOMiPT;
6 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
7 DMT;
8 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
9 MeO-DiPT;
10 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
11 DET; and
12 (I) Dimethyltryptamine, which is also known as DMT; and
13 (31)(A) Any substance containing any quantity of the following
14 materials, compounds, mixtures, or structures:
15 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
16 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
17 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
18 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
19 (v) Fluoromethcathinone, or FMC;
20 (vi) Naphthylpyrovalerone, or naphyrone; or
21 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
22 butylone; or
23 (B) Unless listed in another schedule, any substance which contains
24 any quantity of any material, compound, mixture, or structure, other than
25 bupropion, that is structurally derived by any means from 2-
26 aminopropan-1-one by substitution at the 1-position with either phenyl,
27 naphthyl, or thiophene ring systems, whether or not the compound is
28 further modified in any of the following ways:
29 (i) Substitution in the ring system to any extent with alkyl,
30 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
31 whether or not further substituted in the ring system by one or more
-27-

LB431 LB431
2025 2025
1 other univalent substituents;
2 (ii) Substitution at the 3-position with an acyclic alkyl
3 substituent; or
4 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
5 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
6 structure.
7 (d) Unless specifically excepted or unless listed in another
8 schedule, any material, compound, mixture, or preparation which contains
9 any quantity of the following substances having a depressant effect on
10 the central nervous system, including its salts, isomers, and salts of
11 isomers whenever the existence of such salts, isomers, and salts of
12 isomers is possible within the specific chemical designation:
13 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
14 yl)amino]heptanoic acid, including its salts, isomers, and salts of
15 isomers;
16 (2) Mecloqualone;
17 (3) Methaqualone; and
18 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
19 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
20 Oxybate; and Sodium Oxybutyrate.
21 (e) Unless specifically excepted or unless listed in another
22 schedule, any material, compound, mixture, or preparation which contains
23 any quantity of the following substances having a stimulant effect on the
24 central nervous system, including its salts, isomers, and salts of
25 isomers:
26 (1) Fenethylline;
27 (2) N-ethylamphetamine;
28 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
29 dihydro-5-phenyl-2-oxazolamine;
30 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
31 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
-28-

LB431 LB431
2025 2025
1 (5) Methcathinone, its salts, optical isomers, and salts of optical
2 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
3 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
4 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
5 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
6 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
7 phenyl-2-oxazolamine;
8 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
9 and N,N-alpha-trimethylphenethylamine;
10 (8) Benzylpiperazine, 1-benzylpiperazine;
11 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
12 methyl-5-(4-methylphenyl)-2-oxazolamine); and
13 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
14 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
15 isomers.
16 (f) Kratom.
17 (g) (f) Any controlled substance analogue to the extent intended for
18 human consumption.
19 Schedule II
20 (a) Any of the following substances except those narcotic drugs
21 listed in other schedules whether produced directly or indirectly by
22 extraction from substances of vegetable origin, independently by means of
23 chemical synthesis, or by combination of extraction and chemical
24 synthesis:
25 (1) Opium and opiate, and any salt, compound, derivative, or
26 preparation of opium or opiate, excluding apomorphine, buprenorphine,
27 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
28 naloxone, and naltrexone and their salts, but including the following:
29 (A) Raw opium;
30 (B) Opium extracts;
31 (C) Opium fluid;
-29-

LB431 LB431
2025 2025
1 (D) Powdered opium;
2 (E) Granulated opium;
3 (F) Tincture of opium;
4 (G) Codeine;
5 (H) Ethylmorphine;
6 (I) Etorphine hydrochloride;
7 (J) Hydrocodone;
8 (K) Hydromorphone;
9 (L) Metopon;
10 (M) Morphine;
11 (N) Oxycodone;
12 (O) Oxymorphone;
13 (P) Oripavine;
14 (Q) Thebaine; and
15 (R) Dihydroetorphine;
16 (2) Any salt, compound, derivative, or preparation thereof which is
17 chemically equivalent to or identical with any of the substances referred
18 to in subdivision (1) of this subdivision, except that these substances
19 shall not include the isoquinoline alkaloids of opium;
20 (3) Opium poppy and poppy straw;
21 (4) Coca leaves and any salt, compound, derivative, or preparation
22 of coca leaves, and any salt, compound, derivative, or preparation
23 thereof which is chemically equivalent to or identical with any of these
24 substances, including cocaine or ecgonine and its salts, optical isomers,
25 and salts of optical isomers, except that the substances shall not
26 include decocainized coca leaves or extractions which do not contain
27 cocaine or ecgonine; and
28 (5) Concentrate of poppy straw, the crude extract of poppy straw in
29 either liquid, solid, or powder form which contains the phenanthrene
30 alkaloids of the opium poppy.
31 (b) Unless specifically excepted or unless in another schedule any
-30-

LB431 LB431
2025 2025
1 of the following opiates, including their isomers, esters, ethers, salts,
2 and salts of their isomers, esters, and ethers whenever the existence of
3 such isomers, esters, ethers, and salts is possible within the specific
4 chemical designation, dextrorphan excepted:
5 (1) Alphaprodine;
6 (2) Anileridine;
7 (3) Bezitramide;
8 (4) Diphenoxylate;
9 (5) Fentanyl;
10 (6) Isomethadone;
11 (7) Levomethorphan;
12 (8) Levorphanol;
13 (9) Metazocine;
14 (10) Methadone;
15 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
16 butane;
17 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
18 diphenylpropane-carboxylic acid;
19 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
20 (14) Oliceridine;
21 (15) Pethidine or meperidine;
22 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
23 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
24 carboxylate;
25 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
26 carboxylic acid;
27 (19) Phenazocine;
28 (20) Piminodine;
29 (21) Racemethorphan;
30 (22) Racemorphan;
31 (23) Dihydrocodeine;
-31-

LB431 LB431
2025 2025
1 (24) Bulk Propoxyphene in nondosage forms;
2 (25) Sufentanil;
3 (26) Alfentanil;
4 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
5 acetylmethadol, levomethadyl acetate, and LAAM;
6 (28) Carfentanil;
7 (29) Remifentanil;
8 (30) Tapentadol; and
9 (31) Thiafentanil.
10 (c) Any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a potential for abuse
12 associated with a stimulant effect on the central nervous system:
13 (1) Amphetamine, its salts, optical isomers, and salts of its
14 optical isomers;
15 (2) Phenmetrazine and its salts;
16 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
17 (4) Methylphenidate; and
18 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
19 (d) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substances having a potential for abuse
21 associated with a depressant effect on the central nervous system,
22 including their salts, isomers, and salts of isomers whenever the
23 existence of such salts, isomers, and salts of isomers is possible within
24 the specific chemical designations:
25 (1) Amobarbital;
26 (2) Secobarbital;
27 (3) Pentobarbital;
28 (4) Phencyclidine; and
29 (5) Glutethimide.
30 (e) Hallucinogenic substances known as:
31 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
-32-

LB431 LB431
2025 2025
1 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
2 dibenzo(b,d)pyran-9-one; and
3 (2) Dronabinol in an oral solution in a drug product approved by the
4 federal Food and Drug Administration.
5 (f) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances:
8 (1) Immediate precursor to amphetamine and methamphetamine:
9 Phenylacetone. Trade and other names shall include, but are not limited
10 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
11 ketone;
12 (2) Immediate precursors to phencyclidine, PCP:
13 (A) 1-phenylcyclohexylamine; or
14 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
15 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
16 (ANPP).
17 Schedule III
18 (a) Any material, compound, mixture, or preparation which contains
19 any quantity of the following substances having a potential for abuse
20 associated with a stimulant effect on the central nervous system,
21 including their salts, isomers, whether optical, position, or geometric,
22 and salts of such isomers whenever the existence of such salts, isomers,
23 and salts of isomers is possible within the specific chemical
24 designation:
25 (1) Benzphetamine;
26 (2) Chlorphentermine;
27 (3) Clortermine; and
28 (4) Phendimetrazine.
29 (b) Any material, compound, mixture, or preparation which contains
30 any quantity of the following substances having a potential for abuse
31 associated with a depressant effect on the central nervous system:
-33-

LB431 LB431
2025 2025
1 (1) Any substance which contains any quantity of a derivative of
2 barbituric acid or any salt of a derivative of barbituric acid, except
3 those substances which are specifically listed in other schedules of this
4 section;
5 (2) Aprobarbital;
6 (3) Butabarbital;
7 (4) Butalbital;
8 (5) Butethal;
9 (6) Butobarbital;
10 (7) Chlorhexadol;
11 (8) Embutramide;
12 (9) Lysergic acid;
13 (10) Lysergic acid amide;
14 (11) Methyprylon;
15 (12) Perampanel;
16 (13) Secbutabarbital;
17 (14) Sulfondiethylmethane;
18 (15) Sulfonethylmethane;
19 (16) Sulfonmethane;
20 (17) Nalorphine;
21 (18) Talbutal;
22 (19) Thiamylal;
23 (20) Thiopental;
24 (21) Vinbarbital;
25 (22) Any compound, mixture, or preparation containing amobarbital,
26 secobarbital, pentobarbital, or any salt thereof and one or more other
27 active medicinal ingredients which are not listed in any schedule;
28 (23) Any suppository dosage form containing amobarbital,
29 secobarbital, pentobarbital, or any salt of any of these drugs and
30 approved by the federal Food and Drug Administration for marketing only
31 as a suppository;
-34-

LB431 LB431
2025 2025
1 (24) Any drug product containing gamma-hydroxybutyric acid,
2 including its salts, isomers, and salts of isomers, for which an
3 application is approved under section 505 of the Federal Food, Drug, and
4 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
5 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
6 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
7 cyclohexanone; and
8 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
9 names for a tiletamine-zolazepam combination product shall include, but
10 are not limited to: telazol. Trade or other names for tiletamine shall
11 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
12 cyclohexanone. Trade or other names for zolazepam shall include, but are
13 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
14 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
15 (c) Unless specifically excepted or unless listed in another
16 schedule:
17 (1) Any material, compound, mixture, or preparation containing
18 limited quantities of any of the following narcotic drugs, or any salts
19 calculated as the free anhydrous base or alkaloid, in limited quantities
20 as set forth below:
21 (A) Not more than one and eight-tenths grams of codeine per one
22 hundred milliliters or not more than ninety milligrams per dosage unit,
23 with an equal or greater quantity of an isoquinoline alkaloid of opium;
24 (B) Not more than one and eight-tenths grams of codeine per one
25 hundred milliliters or not more than ninety milligrams per dosage unit,
26 with one or more active, nonnarcotic ingredients in recognized
27 therapeutic amounts;
28 (C) Not more than one and eight-tenths grams of dihydrocodeine per
29 one hundred milliliters or not more than ninety milligrams per dosage
30 unit, with one or more active, nonnarcotic ingredients in recognized
31 therapeutic amounts;
-35-

LB431 LB431
2025 2025
1 (D) Not more than three hundred milligrams of ethylmorphine per one
2 hundred milliliters or not more than fifteen milligrams per dosage unit,
3 with one or more active, nonnarcotic ingredients in recognized
4 therapeutic amounts;
5 (E) Not more than five hundred milligrams of opium per one hundred
6 milliliters or per one hundred grams, or not more than twenty-five
7 milligrams per dosage unit, with one or more active, nonnarcotic
8 ingredients in recognized therapeutic amounts; and
9 (F) Not more than fifty milligrams of morphine per one hundred
10 milliliters or per one hundred grams with one or more active, nonnarcotic
11 ingredients in recognized therapeutic amounts; and
12 (2) Any material, compound, mixture, or preparation containing any
13 of the following narcotic drug or its salts, as set forth below:
14 (A) Buprenorphine.
15 (d) Unless contained on the list of exempt anabolic steroids of the
16 Drug Enforcement Administration of the United States Department of
17 Justice as the list existed on January 31, 2022, any anabolic steroid,
18 which shall include any material, compound, mixture, or preparation
19 containing any quantity of the following substances, including its salts,
20 isomers, and salts of isomers whenever the existence of such salts of
21 isomers is possible within the specific chemical designation:
22 (1) 3-beta,17-dihydroxy-5a-androstane;
23 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
24 (3) 5-alpha-androstan-3,17-dione;
25 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
26 ene);
27 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
28 ene);
29 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
30 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
31 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
-36-

LB431 LB431
2025 2025
1 (9) 4-androstenedione (androst-4-en-3,17-dione);
2 (10) 5-androstenedione (androst-5-en-3,17-dione);
3 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
4 hydroxyandrost-4-en-3-one);
5 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
6 (13) Boldione (androsta-1,4-diene-3,17-3-one);
7 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
8 en-3-one);
9 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
10 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
11 alpha-methyl-androst-1,4-dien-3-one);
12 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
13 en-17-beta-ol) (a.k.a. 'madol');
14 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
15 hydroxy-5-alpha-androst-1-en-3-one);
16 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
17 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
18 androstan-3-one);
19 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
20 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
21 dihydroxyandrost-4-en-3-one);
22 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
23 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
24 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
25 furazan);
26 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
27 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
28 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
29 one);
30 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
31 one);
-37-

LB431 LB431
2025 2025
1 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
2 one);
3 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
4 dien-3-one);
5 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
6 ene);
7 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
8 beta-ol-3-one);
9 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
10 one);
11 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
12 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
13 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
14 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
15 hydroxy-17-beta-hydroxyestr-4-en-3-one);
16 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
17 dien-3-one);
18 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
19 trien-3-one);
20 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
21 en-3-one);
22 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
23 en-3-one);
24 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
25 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
26 methyl-1-testosterone');
27 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
28 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
29 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
30 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
31 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
-38-

LB431 LB431
2025 2025
1 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
2 dione);
3 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
4 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
5 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
6 en-3-one);
7 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
8 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
9 one);
10 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
11 one);
12 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
13 androstan-3-one);
14 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
15 en-3-one);
16 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
17 hydroxy-[5-alpha]-androstan-3-one);
18 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
19 c]pyrazole);
20 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
21 androst-2-eno[3,2-c]-pyrazole);
22 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
23 one);
24 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
25 oic acid lactone);
26 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
27 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
28 hydroxygon-4,9,11-trien-3-one);
29 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
30 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
31 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
-39-

LB431 LB431
2025 2025
1 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
2 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
3 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
4 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
5 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
6 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
7 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
8 beta-ol;
9 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
10 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
11 dione;
12 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
13 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
14 (78) 4-hydroxy-androst-4-ene-3,17-dione;
15 (79) 5 alpha-Androstan-3,6,17-trione;
16 (80) 6-bromo-androst-1,4-diene-3,17-dione;
17 (81) 6-bromo-androstan-3,17-dione;
18 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
19 (83) Delta 1-dihydrotestosterone;
20 (84) Estra-4,9,11-triene-3,17-dione; and
21 (85) Any salt, ester, or ether of a drug or substance described or
22 listed in this subdivision if the salt, ester, or ether promotes muscle
23 growth.
24 (e) Hallucinogenic substances known as:
25 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
26 gelatin capsule in a drug product approved by the federal Food and Drug
27 Administration. Some other names for dronabinol are (6aR-
28 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
29 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
30 Schedule IV
31 (a) Any material, compound, mixture, or preparation which contains
-40-

LB431 LB431
2025 2025
1 any quantity of the following substances, including their salts, isomers,
2 and salts of isomers whenever the existence of such salts, isomers, and
3 salts of isomers is possible within the specific chemical designation:
4 (1) Barbital;
5 (2) Chloral betaine;
6 (3) Chloral hydrate;
7 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
8 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
9 water soluble esterified estrogens);
10 (5) Clonazepam;
11 (6) Clorazepate;
12 (7) Daridorexant;
13 (8) Diazepam;
14 (9) Ethchlorvynol;
15 (10) Ethinamate;
16 (11) Flurazepam;
17 (12) Mebutamate;
18 (13) Meprobamate;
19 (14) Methohexital;
20 (15) Methylphenobarbital;
21 (16) Oxazepam;
22 (17) Paraldehyde;
23 (18) Petrichloral;
24 (19) Phenobarbital;
25 (20) Prazepam;
26 (21) Alprazolam;
27 (22) Bromazepam;
28 (23) Camazepam;
29 (24) Clobazam;
30 (25) Clotiazepam;
31 (26) Cloxazolam;
-41-

LB431 LB431
2025 2025
1 (27) Delorazepam;
2 (28) Estazolam;
3 (29) Ethyl loflazepate;
4 (30) Fludiazepam;
5 (31) Flunitrazepam;
6 (32) Halazepam;
7 (33) Haloxazolam;
8 (34) Ketazolam;
9 (35) Loprazolam;
10 (36) Lorazepam;
11 (37) Lormetazepam;
12 (38) Medazepam;
13 (39) Nimetazepam;
14 (40) Nitrazepam;
15 (41) Nordiazepam;
16 (42) Oxazolam;
17 (43) Pinazepam;
18 (44) Temazepam;
19 (45) Tetrazepam;
20 (46) Triazolam;
21 (47) Midazolam;
22 (48) Quazepam;
23 (49) Zolpidem;
24 (50) Dichloralphenazone;
25 (51) Zaleplon;
26 (52) Zopiclone;
27 (53) Fospropofol;
28 (54) Alfaxalone;
29 (55) Suvorexant;
30 (56) Carisoprodol;
31 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
-42-

LB431 LB431
2025 2025
1 (58) Lemborexant;
2 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
3 (60) Remimazolam; and
4 (61) Serdexmethylphenidate.
5 (b) Any material, compound, mixture, or preparation which contains
6 any quantity of the following substance, including its salts, isomers,
7 whether optical, position, or geometric, and salts of such isomers,
8 whenever the existence of such salts, isomers, and salts of isomers is
9 possible: Fenfluramine.
10 (c) Unless specifically excepted or unless listed in another
11 schedule, any material, compound, mixture, or preparation which contains
12 any quantity of the following substances having a stimulant effect on the
13 central nervous system, including their salts, isomers, whether optical,
14 position, or geometric, and salts of such isomers whenever the existence
15 of such salts, isomers, and salts of isomers is possible within the
16 specific chemical designation:
17 (1) Diethylpropion;
18 (2) Phentermine;
19 (3) Pemoline, including organometallic complexes and chelates
20 thereof;
21 (4) Mazindol;
22 (5) Pipradrol;
23 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
24 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
25 (8) Fencamfamin;
26 (9) Fenproporex;
27 (10) Mefenorex;
28 (11) Modafinil; and
29 (12) Sibutramine.
30 (d) Unless specifically excepted or unless listed in another
31 schedule, any material, compound, mixture, or preparation which contains
-43-

LB431 LB431
2025 2025
1 any quantity of the following narcotic drugs, or their salts or isomers
2 calculated as the free anhydrous base or alkaloid, in limited quantities
3 as set forth below:
4 (1) Propoxyphene in manufactured dosage forms;
5 (2) Not more than one milligram of difenoxin and not less than
6 twenty-five micrograms of atropine sulfate per dosage unit; and
7 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
8 salts, optical and geometric isomers, and salts of these isomers to
9 include: Tramadol.
10 (e) Unless specifically excepted or unless listed in another
11 schedule, any material, compound, mixture, or preparation which contains
12 any quantity of the following substances substance, including their its
13 salts:
14 (1) Pentazocine; and
15 (2) Butorphanol (including its optical isomers).
16 (f) Any material, compound, mixture, or preparation which contains
17 any quantity of the following substance substances, including its salts,
18 isomers, and salts of such isomers, whenever the existence of such salts,
19 isomers, and salts of isomers is possible: Lorcaserin.
20 (g)(1) Unless specifically excepted or unless listed in another
21 schedule, any material, compound, mixture, or preparation which contains
22 any quantity of the following substance, including its salts, optical
23 isomers, and salts of such optical isomers: Ephedrine.
24 (2) The following drug products containing ephedrine, its salts,
25 optical isomers, and salts of such optical isomers, are excepted from
26 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
27 counter, in an area not accessible to customers, or in a locked case so
28 that a customer needs assistance from an employee to access the drug
29 product; (B) are sold by a person, eighteen years of age or older, in the
30 course of his or her employment to a customer eighteen years of age or
31 older with the following restrictions: No customer shall be allowed to
-44-

LB431 LB431
2025 2025
1 purchase, receive, or otherwise acquire more than three and six-tenths
2 grams of ephedrine base during a twenty-four-hour period; no customer
3 shall purchase, receive, or otherwise acquire more than nine grams of
4 ephedrine base during a thirty-day period; and the customer shall display
5 a valid driver's or operator's license, a Nebraska state identification
6 card, a military identification card, an alien registration card, or a
7 passport as proof of identification; (C) are labeled and marketed in a
8 manner consistent with the pertinent OTC Tentative Final or Final
9 Monograph; (D) are manufactured and distributed for legitimate medicinal
10 use in a manner that reduces or eliminates the likelihood of abuse; and
11 (E) are not marketed, advertised, or represented in any manner for the
12 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
13 high, heightened sexual performance, or increased muscle mass:
14 (i) Primatene Tablets; and
15 (ii) Bronkaid Dual Action Caplets.
16 Schedule V
17 (a) Any compound, mixture, or preparation containing any of the
18 following limited quantities of narcotic drugs or salts calculated as the
19 free anhydrous base or alkaloid, which shall include one or more
20 nonnarcotic active medicinal ingredients in sufficient proportion to
21 confer upon the compound, mixture, or preparation valuable medicinal
22 qualities other than those possessed by the narcotic drug alone:
23 (1) Not more than two hundred milligrams of codeine per one hundred
24 milliliters or per one hundred grams;
25 (2) Not more than one hundred milligrams of dihydrocodeine per one
26 hundred milliliters or per one hundred grams;
27 (3) Not more than one hundred milligrams of ethylmorphine per one
28 hundred milliliters or per one hundred grams;
29 (4) Not more than two and five-tenths milligrams of diphenoxylate
30 and not less than twenty-five micrograms of atropine sulfate per dosage
31 unit;
-45-

LB431 LB431
2025 2025
1 (5) Not more than one hundred milligrams of opium per one hundred
2 milliliters or per one hundred grams; and
3 (6) Not more than five-tenths milligram of difenoxin and not less
4 than twenty-five micrograms of atropine sulfate per dosage unit.
5 (b) Unless specifically exempted or excluded or unless listed in
6 another schedule, any material, compound, mixture, or preparation which
7 contains any quantity of the following substances having a stimulant
8 effect on the central nervous system, including its salts, isomers, and
9 salts of isomers: Pyrovalerone.
10 (c) Unless specifically exempted or excluded or unless listed in
11 another schedule, any material, compound, mixture, or preparation which
12 contains any quantity of the following substances having a depressant
13 effect on the central nervous system, including its salts, isomers, and
14 salts of isomers:
15 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
16 acid ethyl ester);
17 (2) Ganaxolone;
18 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
19 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
20 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
21 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
22 salts;
23 (6) Cenobamate; and
24 (7) Lasmiditan.
25 Sec. 3. Original sections 28-401 and 28-405, Revised Statutes
26 Cumulative Supplement, 2024, are repealed.
-46-

[DELETED: yLAa s 2 a 2 R S CSdB1L52]
[DELETED: S 1 S 2 R S C S22c( A m t d a a c s bi i i o a o m t t b o p(d o a p b d n i a c o c0c1k2(3U4( C s m a d b s o5i p i S I t V o s 26C s d n i d s w m7b8m u t F F D a C A 2 U 3 e9s0b1(2c o l o w w a b t3t t n o o i m i n o4d o a l t o a m d o5d o t t p o p w i f m6d o d s s a w t f7p o i r t b t p o o t h b8d9(0( D o D C m t p o t N1S P w a a t e t U C1L52]
[DELETED: S(u o a r s p t a m o i b po c n t p t c s f sd( D m t d o t b a od(0( D m ( a r i t o U1S P o H P o t U2S3( s i f u i t d c m4t5s6s7o8( D o d m t a c o9a0w1(2( M m a p o t p o t g3c4m5i6( M d n i t m s o s p7h t e o i f t p8f9p a o c m s d m o0p o s m s t s s o s p1w i i o g o c c i a d1L52]
[DELETED: p(( W t w o m i r t i t UCs o o c i t p o l ea( M m t p p pci b e f s o n o0i b m o c s o b a c o1e a c s a i a p o2r3M d n i t p o c o 4c5t6i t b u f t m o m o t7p c c p o l o 8c9p a o d o a c s i0t1o2p o o a a i t r t o c3a4( N d m a o t f w p5d6i b m o c s o b a c o7e a c s ( O o p a p8s c l a o ( a c m s9d0s1t1L52]
[DELETED: se t t w n d a u i t U CSc l w e d n c c o e oi( O m a s h a a oa l s t m o b c oc i a d h s a o as0o1a2(3L4( P s m a p e t s o t o5p6(7l8( P m a p a p a 9d a v a p a p a o 0c n m a c r n a 1n2a o p l r o o p t3d d p c r w r t o4a5i t s i a e m s a d i6s7(8h9( I p m a s w i t p0c c u o p p f u a w i a1i c i u o l t b u i t1L52]
[DELETED: mt(( U u m a p w l p chh(( C i m a p o t 0c l e o w a o b o a t1r2g3C4( H o c c m ( t s5r w c o p o f a p o t g6c7s w c t p o m b w o8t9(0i t p o a p a a u t N H1F2p3( H o c c d n i c4c i a d p a b t f F a D5A6( E h d m ( a n d (7t a o p ( p ( a8( s ( p ( a o (9m0(1c1L52]
[DELETED: of i t s i s 2 w l rc s a A p o r idcd( C s a m a s ( tc s o w i s s t t c0s1i2o h e o t c n s t i3s s t o g t t s d4a5S I o S I c s a p i s627h8o9a0(1s2w334f5t6i u f t p u s 5 o t F7F8J9p0( A s m a d o h s1c a p r t t ( t1L52]
[DELETED: ea i a c s i S I o s2en s a h b a b t S o H aH S f s a b i a p pdbs0(1a2s3t p t s 2 C o d n i 4p5(6f7(8b9( R m a p w h a c s0r1o2(3a4b r i a m t d o o5e6(7h8f980( F m a c g b a s t e 1d1L52]
[DELETED: oe( E s h t d f i s8( E t m t o i ie f E t i ct(i0l1a n f o a s n f a s t a2d3(4( C r a m a c c o5s t a t s o m r s6t o a d t p o b a a7o8h b C r a d n i c9c i a d p a b t f F a D0A1(2( A p o t l o t m s p i t3p4(576( ( L s m a p o s n7s8i9t r b t i p e o t h b t0r1c s o t p o o m o t f1L52]
[DELETED: i(t t u w a e h m es o a e o t h b t r om(los0( T p o s i m o a f 1p u o p a t c o t p o s i2d3a4( T p o l o t p o s c5w6i c w s a f l r c7s8(9e t o a t a d o i o t0p1(2a3s i a s d o t c o t p o4s w r o m e o t h b t t5e c p t u o c o a c6s7(8a v o w s t a p c b o9r o t p o s i t t p o0s1( T p o s c a c o c1L52]
[DELETED: c t d n h a l r t t u op c b t s d p o m ott p p o l o d i a o tpS 2 S 2 R S C S22 T f a t s o c sr0c o t l o e p o t D E1A o t U S D o J a t l2e3S4(5e s a s o i e a e u6s e w t e o s i e7e8(9(0(1k2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1( A N1L52]
[DELETED: p p 1p((pi( 1 ( i oi( P 1 i0o1( A N2p3i4( A N5p i o i s a s6o7( B N8i9( B N0p i o i s a s1o2( B ( n N3p i o a4g5( 3 N6p i o a g i7s8( N9(0( T N1p1L52]
[DELETED: ( P Np i o i s a s oi( U 3m(((( A 3 4 c0b1(2(3(4(5(6(7(8(9(0(1y2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((((((0(1(2( B ( n 1 e3p4( F s t i e e5s a s o i e a e U s6e l i a s o s n i t7s t i a s t i s r t8f9(0m1(2a3(4a5( R o t a r w a a m6w7(8( A o t f o d t s i9a s o i u s e w t0e1t1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5a q o t f h s t s6i7e8t9o0( B T a o n s i b a n1l t 3 31L52]
[DELETED: d N 5d( 4 T a o n si b a n l t 4m(a n l t 4 ap( 4 T a o n s0i b a n l t 41m2( P T a o n s3i b a n l t 14a5( I T a o n s i b a n6l t 77m ( a ( i a T8i9(0(1(2(3( P P s m a p o t p p4c5o6e7o8(9(0(1e1L52]
[DELETED: e o c s o s s d at i w s c s a paa t o i e d i a d pa b t f F a D A D 6 c otoo t s i n i s c ot s s b i r o t n0d1i2F3(4(5(6i728(9( P T a o n s i b a n0l t 31d2(3i b a n l t N (4p N5c6( P a o p T a o n7s i b a n l t 18p9(0M a 3 i1a1L52]
[DELETED: (((( S d o S A S d oS A i a p o t p p cb a S d w g o n t st a e f a p o s p a e cm d m o p o s p is0w1p2(3q4( t ( o t s i t s i5s6u s e e i t s S7n o t s p c i n8i9o c o t s s b i u t0s1p2m o s t o a t t s c3p4( T M t n5c6s7r e o c s a s s8d a t i w s c s a9p a s a t f D 1 c o t0t a t o i D 6 c o t1t1L52]
[DELETED: tiF( N A c c a 3ni r b a a h a h bc c 2 gc 1 1p 1 o0t1o2( N A c c a 1 H3y4o5c c 2 g6c 1 17p 1 o8t9o0( N A c c a 31n2p r b a a h a h b3c c 2 g4c 1 15p 1 o6t7o8( N A c c 9n0i r b a a h a h b1c c 2 g1L52]
[DELETED: c 1 1p 1 oto( P A c c a 3p s w s a t n a ot i r b a a h a h bc c 2 gc 1 10p 1 o1t2o3( C A c c a 24h5t p r b a a h a h b6c c 2 g7c 1 18p 1 o9t0t1( B A c c a 32s3a h a h b c4c5p 1 16m o t g w o n7f s i o o a o t l r s t a8e9(0s1a h c a h b1L52]
[DELETED: c c 12m o t g w o nf s i o o a o t l r s t ae( T A c c a 3t s w s a tn a o t i r b a a h ca h b c c 10m 2 11p 1 o2t3o4( I c A c c a 15c s w s a t n a o t6i r b a a h c a h7b c c 18p 2 19p 1 o0t1a a m b p a 12p3s4t a 1 p a b o5p6( I c A c c a 17c s w s a t n a o t8i r b a a h c a h9b c c 10p 2 11p 1 o1L52]
[DELETED: ta a m b p a 1pst a 1 p a b op( A n o s c cm o p n s l e i ts0F a D A c o c a c1r2( Z 13y i i i e e s4a5i e e a s i p w t s6c7(8q o a s p a l i s (9t0a s o s n i t s t i1s d f p b s o t2p r w a f m r f f r o 3f t r b s w t a g b4s5o6s f a c o t f t o7t r s w o n t c i f8m9( S o t p r b a h h a0t1p1L52]
[DELETED: aa(a(a(a(0o1(223(4a5( 2 w i a6k7( 2 w i8a9( 2 w i0a1( 2 w i a k2a3(4k5( 1 w i a6k7(8k9(0k1( 21L52]
[DELETED: mN( 2mN( Nw i a k a M o 3m( 20m w i a k a 2 o122( 23w4( 2 [5y6( 27y8( N t9b w i a k a 20N1( 12w i a k a b o b3d4(5i6(7(8(9a0( 6 w i a1k1L52]
[DELETED: ( 2 w i a k a 2 5d(( 2 w i ak((4(0( 3 w i a k a1M2( 3 w i a k3a4(5( n 4 w6i7(8q9i a s o s n i t s t i0s d f 2 w i a1k2w3i4a t a p w a a g o w o n f5s o t i r t a e w a a a6h7( 5 w i a k a 58D9(0D1(1L52]
[DELETED: H( 4 w i a k a 4H(5(D( 5 w i a k a 5M0(1D2(3( A s c a q o t f4m5(6(7(8(9(0(1( B o b o2b3(4a5b t i s d b a m f 26a7n o t r s w o n t c i8f9( S i t r s t a e w a0a a h h o h s1w o n f s i t r s b o o m1L52]
[DELETED: o( S a t 3 w a a as( S a t 2 n a w a ods( U s e o u l i asa0t1i w t e o s s i a s o2i3( A 74y a i i s i a s o5i6(7(8(9h 4 4 A S0O1( U s e o u l i a2s3a4c n s i i s i a s o5i6(7(8( A a 2 o 49d0( C 2 a1a1L52]
[DELETED: (i S o n 2 a( 2 aN m me( ( a (p( N Na0(1( 4 ( n 4 42m3( N - p4i i i s i a s o5i6(7(8h9S0( A o t f s e t n d1l i o s w p d o i b2e3c s o b c o e a c4s5( O a o a a s c d o6p o o o o e a b7t b d n n8n9(0(1(1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7c8t9s0(1(2o c l a a s c d o p3t4s5a s o o i e t t s s n6i d c l o e w d n c7c8(9e l s o p f w c t p0a1(1L52]
[DELETED: oasc(((((0(1(2(3(4(5( M 46b7( M 28d9(0(1(2(3( P e4c5( P 16c7(8(9(0(1(1L52]
[DELETED: (((( L w i a k a la((((0(1a q o t f s h a p f a2a3( A i s o i a s o i4o5(6(7(8(9(0a q o t f s h a p f a1a w a d e o t c n s2i t s i a s o i w t3e4t5(6(7(8(9(0(1( N A n f n (1L52]
[DELETED: d 6d(f( U s e o u l i asa( I p t a a mP0t P P b m k a m b1k2(3(4(5(6(7S8(9a q o t f s h a p f a0a w a s e o t c n s1i2a3a s o i i p w t s c4d5(6(7(8(9(0a q o t f s h a p f a1a1L52]
[DELETED: ( A s w c a q o a d obts(((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5( A c m o p c a6s7a8( A s d f c a9s p o a s o a o t d a0a1a1L52]
[DELETED: ( A d p c g ai i s i a s o i f w aaC(n f k (c( T a z o a s t T o on0a1i b a n l t 22c3n l t 44t5( U s e o u l i a6s7( A m c m o p c8l9c0a1( N m t o a e g o c p o2h3w4( N m t o a e g o c p o5h6w o o m a n i i r7t8(9o h m o n m t n m p d0u w o o m a n i i r1t1L52]
[DELETED: (hw o o m a n i i rt(m o p o h g o n m t tm p d u w o o m a ni( N m t f m o m p o h0m1i2(3o4(5(6D E A o t U S D o7J8w s i a m c m o p9c0i a s o i w t e o s s o1i2(3(4(5( 1 (6e7( 1 (8e9(0(1(1L52]
[DELETED: ((( B (h(((e(0( D (1a2( D (3e4( D ( '5h6(7( D (8a9(0( F (1d2( F ( (3a4( F (5f6(7(8( 4 (9o0( M (1o1L52]
[DELETED: ( M (o( M (d(e( M (b( M (0o1(2(3(4( 1 (5h6( M (7d8( M (9t0( M (1e2( M (3e4( 1 (5h ( '6m7(8(9(0(1(1L52]
[DELETED: ( 1 (d((( N ( 1e(( N (o0( N (1o2( O (3a4( O (5e6( O (7h8( P (9c0( S (1a2( S (3o4( T (5o6(7( T ( 18h9(0(1(1L52]
[DELETED: ((((((( 2 a 3 a a ab(0( 4 a b1d2(3(4(5(6(7(8(9(0(1(2l3g4(5(6g7A S o n f d a (8t9(0S1(1L52]
[DELETED: aas(((( C b n i l (h a c b o m ( aw0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(1L52]
[DELETED: (((((a q o t f s i i s iw o p o g a s o s iwp0( U s e o u l i a1s2a3c4p5o s s i a s o i i p w t6s7(8(9( P i o c a c0t1(2(3(4(5(6(7(8(9(0( U s e o u l i a1s1L52]
[DELETED: aca(( N m t o m o d a n l tt( 2 is o a g i a s o t i ti0( U s e o u l i a1s2a3s4(5(6(7a8i9i0( U s e o u l i a1s2a q o t f s i i s o3i4( T f d p c e i s5o i a s o s o i a e f6s ( o S I i t ( a s b 7c8t a c n a f a e t a t d9p0c1o1L52]
[DELETED: p r o o a m t t a sg o e b d a t p n cs p r o o a m t n g oeacpm c w t p O T F o FM0u1(2i3h4(5(6S7( A c m o p c a o t8f9f a b o a w s i o o m0n a m i i s p t1c u t c m o p v m2q3(4m5(6h7( N m t o h m o e p o8h9( N m t t a f m o d0a1u1L52]
[DELETED: (m( N m t f m o d a n lt( U s e o e o u l iac a q o t f s h a ses0( U s e o e o u l i1a2c a q o t f s h a d3e4s5( E (6a7(8(9(0( B (1b2s3(4(5S 3  O s 2 a 2 R S6C1L52]